[go: up one dir, main page]

WO2006072370A1 - Selected benzofuran derivatives - Google Patents

Selected benzofuran derivatives Download PDF

Info

Publication number
WO2006072370A1
WO2006072370A1 PCT/EP2005/013344 EP2005013344W WO2006072370A1 WO 2006072370 A1 WO2006072370 A1 WO 2006072370A1 EP 2005013344 W EP2005013344 W EP 2005013344W WO 2006072370 A1 WO2006072370 A1 WO 2006072370A1
Authority
WO
WIPO (PCT)
Prior art keywords
ylmethyl
benzofuran
pyrimidin
dimethoxy
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/013344
Other languages
French (fr)
Inventor
Sorana Greiveldinger-Poenaru
Kalid Islam
Dieter Gillessen
Kaspar Burri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arpida AG
Original Assignee
Arpida AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2007008149A priority Critical patent/MX2007008149A/en
Priority to JP2007549808A priority patent/JP2008526791A/en
Priority to HU0700556A priority patent/HUP0700556A2/en
Priority to EP05819387A priority patent/EP1838704A1/en
Priority to US11/813,241 priority patent/US7524855B2/en
Priority to AU2005324135A priority patent/AU2005324135A1/en
Application filed by Arpida AG filed Critical Arpida AG
Priority to CA002594091A priority patent/CA2594091A1/en
Publication of WO2006072370A1 publication Critical patent/WO2006072370A1/en
Priority to IL183681A priority patent/IL183681A0/en
Priority to NO20073046A priority patent/NO20073046L/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to novel 2,4-diamino-5-(substituted) pyrimidines, to pharmaceutical compositions containing them, to processes for preparing them and their compositions, to intermediates for synthesising them and to their use in the treatment of microbial infections.
  • Trimethoprim 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine
  • U.K. Patent No. 875,562 is the most active antibacterial agent amongst the 2,4-diamino-5-benzylpyrimidines known to date. Due to their mode of action, these benzylpyrimidines potentiate the antibacterial activity of the sulphonamides, and Trimethoprim has been used extensively over the last decade in human therapy in combination with various sulphonamides, and in particular with sulphamethoxazole, for the treatment of bacterial infections.
  • European Patent Applications Nos. 81109631.2 and 83104240.3 disclose inter alia also such types of compounds and their use.
  • a group of novel benzofuran derivatives are more potent than, e.g., Trimethoprim, and are active against Gram positive pathogens (Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis or Streptococcus pneumoniae) and Gram negative pathogens (Haemophilus influenzae, Escherichia coli, Klebsiella pneumoniae, Moraxella Cattharalis or Proteus vulgaris). Furthermore, as mentioned above, the compounds of formula I show significantly improved activity against DHFR including mutated enzyme, a superior bioavailability, and a superior antibacterial activity.
  • R 1 represents the groups
  • R 5 is cyano, carboxylic acid or the group
  • R 9 represents hydrogen, lower alkyloxy, lower alkylamino, lower alkyl with 1 to 6 carbon atoms, aminocarbonylalkyl, mono- or dialkylaminoalkyl, alkyloxyalkyl, arylalkyl, aryl, heteroaryl, whereby the aryl and heteroaryl group optionally are mono- , di- or tri- substituted with straight or branched chain lower alkyl with 1 to 4 carbon atoms, whereby these substituents may be the same or different;
  • R represents hydrogen or lower alkyl with 1 to 4 carbon atoms
  • R 9 and R 10 together with the nitrogen atom to which they are attached, form a 3-, 4-, 5- or 6- membered heterocyclic ring, whereby the 5- or 6- membered rings optionally contain an additional heteroatom which can be the same or different and are oxygen, nitrogen or sulfur, whereby the additional nitrogen can be substituted with lower alkyl with 1 to 4 carbon atoms, mono- or dialkylaminoalkyl or alkyloxyalkyl;
  • R 6 represents hydrogen, halogen, straight or branched chain lower alkyl with 1 to 4 carbon atoms, or lower alkyloxy;
  • R 7 represents hydrogen or halogen
  • R 8 represents hydrogen or straight or branched chain lower alkyl with 1 to 4 carbon atoms
  • R 2 and R 3 independently represent hydrogen; lower alkyl with 1 to 3 carbon atoms; or together a lower alkylene group with 1 to 3 carbon atoms bridging the oxygen atoms and forming a five, six or seven membered ring;
  • R 4 represents hydrogen or lower alkyl with 1 to 4 carbon atoms
  • lower alkyl means straight and branched alkyl chain groups with one to six carbon atoms, preferably 1 to 4 carbon atoms.
  • Examples of lower alkyl and lower alkoxy groups with one to four carbon atom are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec- butyl, tert.-butyl, methoxy, ethoxy, propoxy, butoxy, iso-butoxy, sec- butoxy and tert.-butoxy.
  • heteroaryl means six-membered aromatic rings containing one to four nitrogen atoms, benzo-fused six-membered aromatic rings containing one to three nitrogen atoms, five-membered aromatic rings containing one oxygen or one nitrogen or one sulfur atom, benzo-fused five- membered aromatic rings containing one oxygen or one nitrogen or one sulfur atom, five membered aromatic rings containing an oxygen and nitrogen atom and benzo- fused derivatives thereof, five-membered aromatic rings containing a sulfur and a nitrogen atom and benzo-fused derivatives thereof, five-membered aromatic rings containing two nitrogen atoms and benzo-fused derivatives thereof, five membered aromatic rings containing three nitrogen atoms and benzo-fused derivatives thereof or the tetrazolyl ring, e.g.
  • aryl represents unsubstituted as well as mono-, di- or tri-substituted aromatic rings with 6 to 10 carbon atoms like phenyl or naphthyl rings, which optionally are substituted with C1- C4 lower alkyl.
  • heterocyclic ring represents saturated and unsaturated, but not aromatic, three-membered rings containing one hetero atoms, or four-, five- or six-membered rings containing one or two hetero atoms which may be the same or different and are nitrogen, oxygen or sulfur atoms.
  • halogen means fluorine, chlorine, bromine, and iodine but fluorine, chlorine and bromine are preferred.
  • One preferred group of compounds of the present invention are compounds of the general formula Il
  • R 2 and R 3 represent methyl
  • R 4 represents hydrogen
  • R 5 , R 6 , R 7 and R 8 are as defined in formula I.
  • a further preferred group of compounds of the present invention are compounds of the general formula III
  • R 2 and R 3 represent methyl
  • R 4 represents hydrogen
  • R 5 , R 6 , R 7 and R 8 are as defined in formula I.
  • a further preferred group of compounds of the present invention are compounds of the general formula IV
  • R 2 and R 3 represent methyl
  • R 4 represents hydrogen
  • R 5 , R 6 , R 7 and R 8 are as defined in formula I;
  • a further preferred group of compounds of the present invention are compounds of the general formula V
  • R 2 and R 3 represent methyl
  • R 4 represents hydrogen
  • R 5 , R 6 and R 7 are as defined in formula I;
  • a further preferred group of compounds of the present invention are compounds of the general formula Vl
  • R 2 and R 3 represent methyl
  • R 4 represents hydrogen
  • R 5 , R 6 and R 7 are as defined in formula I; Preferred compounds are compounds of formula I 1 II, III, IV, V and Vl wherein
  • R 5 is carboxylic acid dimethylamide, carboxylic acid methylamide, carboxylic acid diethylamide, carboxylic acid methoxymethylamide, pyrrolidin-1-yl-methanone, morpholin-4-yl-methanone, carboxylic acid methylamide, piperidin-1-yl-methanone; carboxylic acid N-(1 ,3,5-trimethyl-1 H-pyrazol-4-yl)-amide, carboxylic acid N-methyl- benzyl-amide, 4-(2-methoxy-ethyl)-piperazin1-yl-methanone, 4-(2-dimethylamino- ethyl)-piperazin1-yl-methanone, carboxylic acid N-(2-dimethylamino-ethyl)-N-methyl- amide, carboxylic acid N-butyl-N-methyl-amide, carboxylic acid N-isopropyl-N- methyl-amide, carboxylic acid N-carb
  • R 6 represents hydrogen, fluoro, chloro or methoxy
  • R 7 represents hydrogen, fluoro or chloro
  • R 8 represents hydrogen or methyl.
  • Especially preferred compounds are compounds selected from the group consisting of:
  • the invention also relates to a process for the manufacture of compounds of the general formula I
  • R 1 represents the groups
  • R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 have the meaning given in formula I above which process comprises reacting - as depicted in Scheme 1 - a compound of the general formula VII (see PCT Publication WO 02/10157), with the anhydride VIII, wherein R 11 represents straight or branched chain lower alkyl to give the fully protected compound IX.
  • the allyl group of the compound IX is then cleaved using tetrakis(triphenylphosphine)palladium as catalyst, to give the compound of general formula X.
  • the intermediates of the general formula X are novel compounds which serve as intermediates in the synthesis of active compounds of general formula I.
  • the intermediate X (Scheme 2) can be coupled with the corresponding anthranilic acid derivatives Xl under acidic conditions, such as p-toluenesulfonic acid, to give to the compound of general formula XII, wherein R 1 is defined as in formula I.
  • Treatment of the compound XII with an excess of aqueous sodium hydroxide solution gives the desired compound of general formula I.
  • R 5 represents the group
  • R 6 , R 7 , R 8 , R 9 and R 10 have the meaning given in formula I above, are synthesised by reacting the anthranilic acids XIII, (which, when R 8 represents lower alkyl, can be obtained by the reductive amination reaction with the corresponding aldehyde according to General Procedure C (compare experimental part)), with the amine XIV using standard peptide coupling reagents such as N-Ethyl-N'(3- dimethylaminipropyl)carbodiimide hydrochloric acid salt (EDC) and 1- Hydroxybenzotrialzole (HOBT) or 0-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU) as described in Scheme 3.
  • EDC N-Ethyl-N'(3- dimethylaminipropyl)carbodiimide hydrochloric acid salt
  • HOBT 1- Hydroxybenzot
  • R 5 COOH Access to an alternative array of substituents can be achieved by proceeding according to Scheme 4.
  • the intermediates of the general formula XVI are novel compound which serve as intermediates in the synthesis of active compounds of general formula I.
  • the alcohol X was activated by reacting it with sulfonyl chloride compounds of formula XV, wherein R 12 represents lower alkyl or aryl, to give the intermediate XVI.
  • the compound XVI thus obtained was reacted with the anthranilic acid derivatives Xl, using Lewis acids such as ZnCI 2 , to give the compound XII. Further treatment with aqueous base gave the compound of general formula I as described in Scheme 4.
  • the intermediates of the general XVII are novel compounds, which serve as intermediates in the synthesis of active compounds of general formula I.
  • the alcohol X was oxidized using an excess of manganese dioxide to give the aldehyde XVII.
  • the compound XVII thus obtained was reacted with the anthanilic acid derivative Xl, using reductive amination conditions.
  • the Schiff base was formed under acidic conditions, or adding triethylorthoformate as dehydrating agent and it was then reduced with sodium borohydride to give the compound of formula XII.
  • Final treatment with base gave the compound of general formula I as described in Scheme 5.
  • the invention also relates to a process for the manufacture of compounds of the general formula I
  • R 1 represents the groups
  • R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 have the meaning given in formula I above, which process comprises reacting under basic conditions - as depicted in Scheme 7 - a compound of the general formula XX (see PCT Publication WO 02/10157), with the corresponding anthranilic acid derivatives or phenol XXI, wherein Z represents, NHR 8 Or OH.
  • ACN Acetonitrile ATCC: American type culture collection
  • KHSO 4 Potassium hydrogen sulfate
  • TLC Thin layer chromatography
  • TBTU 0-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate
  • Example 1 Following General Procedure A, N-[5-(2-allyloxymethyl-6,7-dimethoxy-benzofuran-4- ylmethyl)-4-(2,2-dimethyl-propionylamino)-pyrimidin-2-yl]-2,2-dimethyl-propionamide (quantitative yield from HPLC-MS profile) was obtained as a brown oil by reacting (5- (2-allyloxymethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)-pyrimidine-2,4-diamine) (1 eq., 5 g, 13.5mmol) and pivalic acid anhydride (2.5 eq., 7.0 ml_, 34.5 mmol). MS ESI: 539.2 [M+H] +
  • 2-amino-4-chloro-N-(1 ,3,5-trimethyl-1 H-pyrazol-4- yl)-benzamide (164 mg, 72 %) was obtained by reacting 2-amino-4-chloro-benzoic acid (140 mg, 0.79 mmol), 1 ,3,5-trimethyl-1 H-pyrazol-4-ylamine (500 mg, 3.99 mmol), 1-hydroxybenzotriazole hydrate (130 mg, 0.96 mmol), (3-dimethylamino- propyl)-ethyl-carbodiimide hydrochloride (183 mg, 0.96 mmol), and triethylamine (220 ⁇ l_, 1.60 mmol).
  • 2-amino-4-fluoro-N,N-dimethyl-benzamide (quantitative yield from HPLC-MS profile) was obtained by reacting 2-amino-4-fluoro- benzoic acid (1 g, 6.44 mmol), dimethylamine hydrochloride (630 mg, 7.73 mmol), 1- hydroxybenzotriazole hydrate (1.04 g, 7.73 mmol), (3-dimethylamino-propyl)-ethyl- carbodiimide hydrochloride (1.48 g, 7.73 mmol), and triethylamine (2.68 mL, 19.3 mmol).
  • 2-amino-4-chloro-N,N-dimethyl-benzamide (10.36 g, 89%) was obtained by reacting 2-amino-4-chloro-benzoic acid (10 g, 58.3 mmol), dimethylamine hydrochloride (5.71 g, 70.0 mmol), 1-hydroxybenzotriazole hydrate (9.45 g, 70.0 mmol), (3-dimethylamino-propyl)-ethyl-carbodiimide hydrochloride (13.41 g, 70.0 mmol), and triethylamine (24.3 mL, 70.0 mmol).
  • MS ESI 199.0 [M+H] +
  • 2-amino-6-fluoro-N,N-dimethyl-benzamide (1.78 g, 76 %) was obtained by reacting 2-amino-6-fluoro-benzoic acid (2 g, 12.9 mmol), dimethylamine hydrochloride (1.26 g, 15.9 mmol), 1-hydroxybenzotriazole hydrate
  • 2-amino-3-chloro-N,N-dimethyl-benzamide (750 mg, 65 %) was obtained by reacting 2-amino-3-chloro-benzoic acid (1 g, 5.83 mmol), dimethylamine hydrochloride (571 mg, 7.00 mmol), 1 -hydroxybenzotriazole hydrate (945 mg, 7.00 mmol), (3-dimethylamino-propyl)-ethyl-carbodiimide hydrochloride (1.34 g, 7.00 mmol) and triethylamine (2.43 ml_, 17.49 mmol).
  • MS ESI 199.0 [M+H] +
  • 5-fluoro-2-hydroxy-N,N-dimethyl-benzamide (1.02 g, 43%) was obtained by reacting 5-fluoro-2-hydroxy-benzoic acid (2 g, 12.8 mmol), dimethylamine hydrochloride (1.25 g, 15.36 mmol), 1-hydroxybenzotriazole hydrate (2.07 g, 15.36 mmol), (3-dimethylamino-propyl)-ethyl-carbodiimide hydrochloride (2.94 g, 15.36 mmol) and triethylamine (4.88 mL, 38.78 mmol).
  • MS ESI 184.0 [M+H] +
  • Example 19 Following General Procedure D, (2-amino-4-chloro-phenyl)-morpholin-4-yl- methanone (quantitative yield from HPLC-MS profile) was obtained by reacting 2- amino-4-chloro-benzoic acid (100 mg, 0.58 mmol), morpholine (61 ⁇ l_, 0.70 mmol), 1- hydroxybenzotriazole hydrate (95 mg, 0.70 mmol), (3-dimethylamino-propyl)-ethyl- carbodiimide hydrochloride (134 mg, 0.70 mmol) and triethylamine (161 ⁇ l_, 1.16 mmol).
  • the compound XII (1 eq.) so obtained was dissolved in methanol or isopropanol and an excess of a 4N NaOH solution (10 eq.) was added. The resulting mixture was heated at 50 0 C until completion. The reaction was quenched with water, and extracted with dichloromethane. The organic layer was washed with a saturated solution of NaHCO 3 , water, and brine, and it was dried over MgSO 4 and evaporated under reduced pressure.
  • the compound I was obtained after purification by FC, eluting with a gradient from CH 2 CI 2 to CH 2 CI 2 /methanol (9/1).
  • N-benzyl-4-chloro-2- ⁇ [4-(2,4-diamino-pyrimidin-5- ylmethyl)-6,7-dimethoxy-benzofuran-2-ylrnethyl]-amino ⁇ -N-methyl-benzamide 60 mg, 25% was obtained by reacting N-[2-(2,2-dimethyl-propionylamino)-5-(2- hydroxymethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)-pyrimidin-4-yl]-2,2-dimethyl- propionamide (200 mg, 0.40 mmol), p-toluenesulfonic acid (191 mg, 1.00 mmol), 2- amino-N-benzyl-4-chloro-N-methyl-benzamide (150 mg, 0.40 mmol), and 4N NaOH (757 ⁇ l_, 3.03 mmol).
  • MS ESI 586.9 [M+Hf
  • the compound XII (1 eq.) so obtained was dissolved in methanol or isopropanol and an excess of a 4N NaOH solution (10 eq.) was added. The resulting mixture was heated at 50 0 C until completion. The reaction was quenched with water, and extracted with dichloromethane. The organic layer was washed with a saturated solution of NaHCO 3 , water, brine, dried over MgSO 4 and evaporated under reduced pressure.
  • the compound I was obtained after purification by FC, eluting with a gradient from CH 2 CI 2 to CH 2 CI 2 /methanol (9/1).
  • Example 28 Following General Procedure G, 4-chloro-2- ⁇ [4-(2,4-diamino-pyrimidin-5-ylmethyl)- 6,7-dimethoxy-benzofuran-2-ylmethyl]-amino ⁇ -N,N-dimethyl-benzamide (2 g, 76 %) was obtained by reacting N-[2-(2,2-dimethyl-propionylamino)-5-(2-hydroxymethyl-6,7- dimethoxy-benzofuran-4-ylmethyl)-pyrimidin-4-yl]-2,2-dimethyl-propionamide (2.57 g, 5.15 mmol), methanesulfonyl chloride (480 ⁇ l_, 6.18 mmol), triethylamine (861 ⁇ L, 6.18 mmol), zinc chloride (840 mg, 6.18 mmol), 2-amino-4-chloro-N,N-dimethyl- benzamide (1.23 g, 6.18 mmol), and 4N NaOH (2.42
  • Example 31 Following General Procedure G, 4-chloro-2- ⁇ [4-(2,4-diamino-pyrimidin-5-ylmethyl)- 6,7-dimethoxy-benzofuran-2-ylmethyl]-methyl-amino ⁇ -N-methyl-benzamide (52 mg, 17%) was obtained by reacting N-[2-(2,2-dimethyl-propionylamino)-5-(2- hydroxymethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)-pyrimidin-4-yl]-2,2-dimethyl- propionamide (300 mg, 0.60 mmol), methanesulfonyl chloride (56 ⁇ L, 0.72 mmol), triethylamine (100 ⁇ L, 0.72 mmol), zinc chloride (98 mg, 0.72 mmol), 4-chloro-N- methyl-2-methylamino-benzamide (143 mg, 0.72 mmol), and 4N NaOH (318 ⁇ l_, 1.27 mmol).
  • Example 38 Following General Procedure H, N-[2-(2,2-dimethyl-propionylamino)-5-(2-formyl-6,7- dimethoxy-benzofuran-4-ylmethyl)-pyrimidin-4-yl]-2,2-dimethyl-propionamide (650 mg, 27%) was obtained by reacting N-[2-(2,2-dimethyl-propionylamino)-5-(2- hydroxymethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)-pyrimidin-4-yl]-2,2-dimethyl- propionamide (2.85 g, 5.73 mmol) and manganese dioxide (5.0 g, 57.37 mmoi). MS ESI: 497.1 [M+H] +
  • the compound (1 eq.) obtained following the general procedure J was dissolved in methanol or isopropanol and an excess of a 4N NaOH solution (4 to 10 eq.) was added. The resulting mixture was heated at 5O 0 C. After completion, the reaction was quenched with water and extracted with dichloromethane. The organic layer was 0 washed with a saturated solution of NaHCO 3 , water, brine, dried over MgSO 4 , and evaporated under reduced pressure.
  • the compound I was obtained after purification by FC, eluting with a gradient from CH 2 CI 2 to CH 2 CI 2 /methanol (9/1).
  • Example 45 5 Following General Procedure K, 4-chloro-2- ⁇ [4-(2,4-diamino-pyrimidin-5-ylmethyl)- 6,7-dimethoxy-benzofuran-2-ylmethyl]-amino ⁇ -benzoic acid (10 mg, 13%) was obtained by reacting the mixture XIX (see scheme 6) containing 2- ⁇ [4-(2,4-Bis- isobutyrylamino-pyrirnidin-S-ylmethyl ⁇ .y-climethoxy-benzofuran ⁇ -ylrnethylJ-amino ⁇ - 4-chloro-benzoic acid and 2- ⁇ [4-(2-Amino-4-isobutyrylamino-pyrimidin-5-ylmethyl)- 6,7-dimethoxy-benzofuran-2-ylmethyl]-amino ⁇ -4-chloro-benzoic acid (ratio 1 :2) described in the general procedure J (100 mg, 0.16 mmol) and 4 N NaOH (
  • Example 46 Following General Procedure K, 4-chloro-2- ⁇ [4-(2,4-diamino-pyrimidin-5-ylmethyl)- 6,7-dimethoxy-benzofuran-2-ylmethyl]-amino ⁇ -N-isopropyl-N-methyl-benzamide (908 mg, 28.5%) was obtained by reacting 2- ⁇ [4-(2-amino-4-isobutyrylamino-pyrimidin-5- ylmethyO- ⁇ y-dimethoxy-benzofuran ⁇ -ylmethyll-aminoJ ⁇ -chloro-N-isopropyl-N- methyl-benzamide (3.6 g, 5.9 mmol) and 4N NaOH (5.34 ml_, 21.36 mmol) MS ESI: 539.0 [M+H] +
  • the compound (1 eq.) so obtained was dissolved in methanol or isopropanol and an excess of a 4N NaOH solution (6 eq.) was added.
  • the resulting mixture was heated at 50 0 C overnight or 10 minutes at 11O 0 C in the microwave.
  • the reaction was quenched with water and extracted with dichloromethane.
  • the organic layer was washed with a saturated solution of NaHCO 3 , water, brine, dried over MgSO 4 , and evaporated under reduced pressure.
  • the compound I was obtained after purification by FC, eluting with a gradient from CH 2 CI 2 to CH 2 CI 2 /methanol (9/1).
  • N-butyl-4-chloro-2- ⁇ [4-(2,4-diamino-pyrimidin-5- ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-amino ⁇ -N-methyl-benzamide (16 mg, 9%) was obtained by reacting mixture XIX (see scheme 6) containing 2- ⁇ [4-(2,4-bis- isobutyrylamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-amino ⁇ - 4-chloro-benzoic acid and 2- ⁇ [4-(2-amino-4-isobutyrylamino-pyrimidin-5-ylmethyl)- 6,7-dimethoxy-benzofuran-2-ylmethyl]-amino ⁇ -4-chloro-benzoic acid (ratio 1 :2) (200 mg, 0.32 mmol), 1 -hydroxybenzotriazole hydrate (52 mg,
  • N-carbamoylmethyl-4-chloro-2- ⁇ [4-(2,4-diamino- pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-amino ⁇ -N-methyl- benzamide (7 mg, 3%) was obtained by reacting N-[5-(2-formyl-6,7-dimethoxy- benzofuran-4-ylmethyl)-2-isobutyrylamino-pyrimidin-4-yl]-isobutyramide (200 mg, 0.43 mmol), 2-amino-N-carbamoylmethyl-4-chloro-N-methyl-benzamide (103 mg, 0.43 mmol), triethylorthoformate (130 ⁇ L, 1.19 mmol) and NaBH 4 (64 mg, 1.71 mmol) MS ESI: 554.1 [M+H] +

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

The invention relates to new benzofuran derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds, and especially their use as anti-infectives.

Description

Selected Benzofuran Derivatives
The present invention relates to novel 2,4-diamino-5-(substituted) pyrimidines, to pharmaceutical compositions containing them, to processes for preparing them and their compositions, to intermediates for synthesising them and to their use in the treatment of microbial infections.
Certain 2,4-diamino-5-benzylpyrimidines have been demonstrated to be potent inhibitors of dihydrofolate reductase (DHFR), which catalyses the reduction of dihydrofolic acid to tetrahydrofolic acid (THFA). This property has been shown to result frequently in useful pharmaceutical properties particularly in the treatment of bacterial infections. Thus, U.K. Patent Specification No. 875,562 discloses inter alia 2,4-diamino-5-benzylpyrimidines wherein the benzyl moiety is substituted by three C1-4 alkoxy groups.
Trimethoprim, 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine, is specifically disclosed in U.K. Patent No. 875,562 and is the most active antibacterial agent amongst the 2,4-diamino-5-benzylpyrimidines known to date. Due to their mode of action, these benzylpyrimidines potentiate the antibacterial activity of the sulphonamides, and Trimethoprim has been used extensively over the last decade in human therapy in combination with various sulphonamides, and in particular with sulphamethoxazole, for the treatment of bacterial infections.
European Patent Applications Nos. 81109631.2 and 83104240.3 disclose inter alia also such types of compounds and their use.
In WO 02/10157 similar compounds are described. However, the compounds disclosed hereinafter exhibit a much more potent activity against DHFR including mutated enzyme, a superior bioavailability, and a superior antibacterial activity.
Thus, it has been found that a group of novel benzofuran derivatives are more potent than, e.g., Trimethoprim, and are active against Gram positive pathogens (Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis or Streptococcus pneumoniae) and Gram negative pathogens (Haemophilus influenzae, Escherichia coli, Klebsiella pneumoniae, Moraxella Cattharalis or Proteus vulgaris). Furthermore, as mentioned above, the compounds of formula I show significantly improved activity against DHFR including mutated enzyme, a superior bioavailability, and a superior antibacterial activity.
Therefore, the present invention relates to novel compounds of the general formula I
Figure imgf000003_0001
Formula I wherein
R1 represents the groups
Figure imgf000003_0002
whereby in these groups R5 is cyano, carboxylic acid or the group
AN-'
R 10
R9 represents hydrogen, lower alkyloxy, lower alkylamino, lower alkyl with 1 to 6 carbon atoms, aminocarbonylalkyl, mono- or dialkylaminoalkyl, alkyloxyalkyl, arylalkyl, aryl, heteroaryl, whereby the aryl and heteroaryl group optionally are mono- , di- or tri- substituted with straight or branched chain lower alkyl with 1 to 4 carbon atoms, whereby these substituents may be the same or different;
R represents hydrogen or lower alkyl with 1 to 4 carbon atoms; R9 and R10 together with the nitrogen atom to which they are attached, form a 3-, 4-, 5- or 6- membered heterocyclic ring, whereby the 5- or 6- membered rings optionally contain an additional heteroatom which can be the same or different and are oxygen, nitrogen or sulfur, whereby the additional nitrogen can be substituted with lower alkyl with 1 to 4 carbon atoms, mono- or dialkylaminoalkyl or alkyloxyalkyl;
R6 represents hydrogen, halogen, straight or branched chain lower alkyl with 1 to 4 carbon atoms, or lower alkyloxy;
R7 represents hydrogen or halogen;
R8 represents hydrogen or straight or branched chain lower alkyl with 1 to 4 carbon atoms;
R2 and R3 independently represent hydrogen; lower alkyl with 1 to 3 carbon atoms; or together a lower alkylene group with 1 to 3 carbon atoms bridging the oxygen atoms and forming a five, six or seven membered ring;
R4 represents hydrogen or lower alkyl with 1 to 4 carbon atoms;
and pharmaceutically acceptable salts thereof.
In the definitions of the general formula I - if not otherwise stated - the expression lower alkyl means straight and branched alkyl chain groups with one to six carbon atoms, preferably 1 to 4 carbon atoms. Examples of lower alkyl and lower alkoxy groups with one to four carbon atom are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec- butyl, tert.-butyl, methoxy, ethoxy, propoxy, butoxy, iso-butoxy, sec- butoxy and tert.-butoxy. The expression heteroaryl means six-membered aromatic rings containing one to four nitrogen atoms, benzo-fused six-membered aromatic rings containing one to three nitrogen atoms, five-membered aromatic rings containing one oxygen or one nitrogen or one sulfur atom, benzo-fused five- membered aromatic rings containing one oxygen or one nitrogen or one sulfur atom, five membered aromatic rings containing an oxygen and nitrogen atom and benzo- fused derivatives thereof, five-membered aromatic rings containing a sulfur and a nitrogen atom and benzo-fused derivatives thereof, five-membered aromatic rings containing two nitrogen atoms and benzo-fused derivatives thereof, five membered aromatic rings containing three nitrogen atoms and benzo-fused derivatives thereof or the tetrazolyl ring, e.g. furanyl, thienyl, pyrrolyl, pyridinyl, indolyl, quinolinyl, isoquinolinyl, imidazolyl, triazinyl, thiazinyl, thiazolyl, isothiazolyl, pyridazinyl, pyrazolyl, oxazolyl, isoxazolyl, etc. whereby such rings optionally are substituted with lower alkyl containing 1 to 4 carbon atoms. The expression aryl represents unsubstituted as well as mono-, di- or tri-substituted aromatic rings with 6 to 10 carbon atoms like phenyl or naphthyl rings, which optionally are substituted with C1- C4 lower alkyl. The expression heterocyclic ring represents saturated and unsaturated, but not aromatic, three-membered rings containing one hetero atoms, or four-, five- or six-membered rings containing one or two hetero atoms which may be the same or different and are nitrogen, oxygen or sulfur atoms. Examples are piperidinyl, morpholinyl, piperazinyl, pyrrolidinyl, dihydroimidazolyl, dihydropyrazoyl, pyrazolidinyl or dihydroxazolinyl, aziridine, azetidine. The expression halogen means fluorine, chlorine, bromine, and iodine but fluorine, chlorine and bromine are preferred.
One preferred group of compounds of the present invention are compounds of the general formula Il
Figure imgf000005_0001
wherein
R2 and R3 represent methyl;
R4 represents hydrogen;
R5, R6, R7 and R8 are as defined in formula I.
A further preferred group of compounds of the present invention are compounds of the general formula III
Figure imgf000006_0001
Formula III
wherein
R2 and R3 represent methyl;
R4 represents hydrogen and
R5, R6, R7 and R8 are as defined in formula I.
A further preferred group of compounds of the present invention are compounds of the general formula IV
Figure imgf000006_0002
wherein
R2 and R3 represent methyl;
R4 represents hydrogen and
R5, R6, R7 and R8 are as defined in formula I; A further preferred group of compounds of the present invention are compounds of the general formula V
Figure imgf000007_0001
wherein
R2 and R3 represent methyl;
R4 represents hydrogen and
R5, R6 and R7 are as defined in formula I;
A further preferred group of compounds of the present invention are compounds of the general formula Vl
Figure imgf000007_0002
Formula Vl
wherein
R2 and R3 represent methyl;
R4 represents hydrogen and
R5, R6 and R7 are as defined in formula I; Preferred compounds are compounds of formula I1 II, III, IV, V and Vl wherein
R5 is carboxylic acid dimethylamide, carboxylic acid methylamide, carboxylic acid diethylamide, carboxylic acid methoxymethylamide, pyrrolidin-1-yl-methanone, morpholin-4-yl-methanone, carboxylic acid methylamide, piperidin-1-yl-methanone; carboxylic acid N-(1 ,3,5-trimethyl-1 H-pyrazol-4-yl)-amide, carboxylic acid N-methyl- benzyl-amide, 4-(2-methoxy-ethyl)-piperazin1-yl-methanone, 4-(2-dimethylamino- ethyl)-piperazin1-yl-methanone, carboxylic acid N-(2-dimethylamino-ethyl)-N-methyl- amide, carboxylic acid N-butyl-N-methyl-amide, carboxylic acid N-isopropyl-N- methyl-amide, carboxylic acid N-carbamoylmethyl-N-methyl-amide , carboxylic acid or cyano;
R6 represents hydrogen, fluoro, chloro or methoxy;
R7 represents hydrogen, fluoro or chloro;
R8 represents hydrogen or methyl.
Especially preferred compounds are compounds selected from the group consisting of:
(4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-phenyl)-pyrrolidin-1-yl-methanone 4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-N,N-diethyl-benzamide
(4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-phenyl)-piperidin-1-yl-methanone
4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-N-(1 ,3,5-trimethyl-1 H-pyrazol-4-yl)-benzamide
N-Benzyl-4-chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy- benzofuran-2-ylmethyl]-amino}-N-methyl-benzamide
4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-N,N-dimethyl-benzamide 5-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-N,N-dimethyl-benzamide
4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-methyl-amino}-N,N-dimethyl-benzamide
4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-methyl-amino}-N-methyl-benzamide
2-{[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]- methyl-amino}-4-fluoro-N,N-dimethyl-benzamide 2-{[4-(2,4-Diannino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylnnethyl]- amino}-5,N,N-trimethyl-benzamide
2-{[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]- amino}-6-fluoro-N,N-dimethyl-benzamide 2-{[4-(2,4-Diamino-pyrimidin-5-y!methyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]- amino}-N,N-dimethyl-benzamide
2-{[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]- amino}-4-fluoro-N,N-dimethyl-benzannide
3-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-N,N-dimethyl-benzamide
3,5-Dichloro-2-[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethoxy]-N,N-dimethyl-benzamide
4-Chloro-2-[4-(2,4-diamino-pyrimidin-5-ylnnethyl)-6,7-dimethoxy-benzofuran-2- ylmethoxy]-N-methyl-benzamide 2-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethoxy]-5- fluoro-N,N-dimethyl-benzamide
2-{[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]- amino}-3-methoxy-N,N-dimethyl-benzannide
2-{[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyi]- methyl-amino}-N,N-dimethyl-benzamide
3,6-Dichloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-N,N-dimethyl-benzamide
4-Chloro-2-[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethoxy]-N,N-dimethyl-benzamide (4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-phenyl)-morpholin-4-yl-methanone
4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-benzonitrile
4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-N-isopropyl-N-methyl-benzamide
N-ButyM-chloro^-^^^-diamino-pyrimidin-S-ylmethyO-βJ-dimethoxy-benzofuran-
2-ylmethyl]-amino}-N-methyl-benzamide
4-Chloro-2-{[4-(2,4-diamino-pyriπnidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-benzoic acid 4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-N-(2-dimethylamino-ethyl)-N-methyl-benzamide (4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-phenyl)-[4-(2-dimethylamino-ethyl)-piperazin-1-y|]-nnethanone
(4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-phenylH4-(2-methoxy-ethyl)-piperazin-1-yl]-nnethanone
N-CarbamoylmethyW-chloro^-^^^-diamino-pyrimidin-δ-ylmethyO-ej-dimethoxy- benzofuran-2-ylmethyl]-amino}-N-methyl-benzamide
and pharmaceutically acceptable salts thereof.
The invention also relates to a process for the manufacture of compounds of the general formula I
Figure imgf000011_0001
wherein
R1 represents the groups
Figure imgf000011_0002
wherein
R2, R3, R4, R5, R6, R7, and R8 have the meaning given in formula I above which process comprises reacting - as depicted in Scheme 1 - a compound of the general formula VII (see PCT Publication WO 02/10157), with the anhydride VIII, wherein R11 represents straight or branched chain lower alkyl to give the fully protected compound IX. The allyl group of the compound IX is then cleaved using tetrakis(triphenylphosphine)palladium as catalyst, to give the compound of general formula X.
Scheme 1
Figure imgf000012_0001
The intermediates of the general formula X are novel compounds which serve as intermediates in the synthesis of active compounds of general formula I. The intermediate X (Scheme 2) can be coupled with the corresponding anthranilic acid derivatives Xl under acidic conditions, such as p-toluenesulfonic acid, to give to the compound of general formula XII, wherein R1 is defined as in formula I. Treatment of the compound XII with an excess of aqueous sodium hydroxide solution gives the desired compound of general formula I.
Scheme 2
Figure imgf000012_0002
Formula I Some of the unknown anthranilic acid derivatives of general formula Xl,
Figure imgf000013_0001
wherein R5 represents the group
υ
^R9
Mo
and R6, R7, R8, R9 and R10 have the meaning given in formula I above, are synthesised by reacting the anthranilic acids XIII, (which, when R8 represents lower alkyl, can be obtained by the reductive amination reaction with the corresponding aldehyde according to General Procedure C (compare experimental part)), with the amine XIV using standard peptide coupling reagents such as N-Ethyl-N'(3- dimethylaminipropyl)carbodiimide hydrochloric acid salt (EDC) and 1- Hydroxybenzotrialzole (HOBT) or 0-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU) as described in Scheme 3. The anthranilic acid derivatives Xl thus obtained are coupled with the compounds X, using the same procedure as described above in Scheme 2, to give the compound of general formula I.
Scheme 3
Figure imgf000013_0002
R5 = COOH Access to an alternative array of substituents can be achieved by proceeding according to Scheme 4.
Scheme 4
Figure imgf000014_0001
Figure imgf000014_0003
Figure imgf000014_0002
Formula I XII
The intermediates of the general formula XVI are novel compound which serve as intermediates in the synthesis of active compounds of general formula I. The alcohol X was activated by reacting it with sulfonyl chloride compounds of formula XV, wherein R12 represents lower alkyl or aryl, to give the intermediate XVI. The compound XVI thus obtained was reacted with the anthranilic acid derivatives Xl, using Lewis acids such as ZnCI2, to give the compound XII. Further treatment with aqueous base gave the compound of general formula I as described in Scheme 4.
Access to an alternative array of substituents can also be achieved by following the synthetic Scheme 5.
The intermediates of the general XVII are novel compounds, which serve as intermediates in the synthesis of active compounds of general formula I. The alcohol X was oxidized using an excess of manganese dioxide to give the aldehyde XVII. The compound XVII thus obtained was reacted with the anthanilic acid derivative Xl, using reductive amination conditions. The Schiff base was formed under acidic conditions, or adding triethylorthoformate as dehydrating agent and it was then reduced with sodium borohydride to give the compound of formula XII. Final treatment with base gave the compound of general formula I as described in Scheme 5.
Scheme 5
Figure imgf000015_0001
Figure imgf000015_0002
Formula I
Figure imgf000015_0003
An alternative procedure can be used to synthesise the compounds of general formula I. The compound XVII was reacted with the aniline XVIII, wherein R5 is define as in forluma I, using reductive amination conditions. The Schiff base was formed under strong acidic conditions, such as trifluoroacetic acid, and it was then reduced with sodium borohydridetriacetoxy to give the mixture XIX as describe in Scheme 6. In the specific case of R5 being carboxylic acid, a further coupling with the corresponding amines XIV using standard amide coupling procedures with O- (benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU) as coupling reagent was performed. Final treatment with base gave the compound of general formula I as described in Scheme 6. Scheme 6
Figure imgf000016_0001
Mixture XIX
TBTU; to follow 1 and 2 , CN or amide to follow 2
Figure imgf000016_0002
The invention also relates to a process for the manufacture of compounds of the general formula I
Figure imgf000016_0003
Formula I
wherein R1 represents the groups
Figure imgf000017_0001
and R2, R3, R4, R5, R6, R7 and R8 have the meaning given in formula I above, which process comprises reacting under basic conditions - as depicted in Scheme 7 - a compound of the general formula XX (see PCT Publication WO 02/10157), with the corresponding anthranilic acid derivatives or phenol XXI, wherein Z represents, NHR8 Or OH.
Scheme 7
Figure imgf000017_0002
Formula I
Experimental part Abbreviations:
ACN: Acetonitrile ATCC: American type culture collection
CH2CI2: Dichloromethane
DMF: Dimethyl formamide
DMSO: Dimethyl sulfoxide
EDC: N-Ethyl-N'(3-dimethylaminipropyl)carbodiimide hydrochloric acid salt eq.: equivalent
ESI: Electrospray ionisation
EtOH: Ethanol
FC: Flash chromatography
HOBT: 1-hydroxybenzotriazole HPLC: High performance liquid chromatography
KHSO4: Potassium hydrogen sulfate
MeOH: Methanol
MgSO4: Magnesium sulfate
MS: Mass spectrometry NMR: Nuclear magnetic resonance p-TosOH: p-toluenesulfonic acid
TFA: Trifluoroacetic acid
THF: Tetrahydrofuran
TLC: Thin layer chromatography TBTU: 0-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate
General Procedure A: Protection of Diaminopyrimidine group (Scheme 1)
Under argon and at room temperature, compound VII (1 eq.) was suspended in the anhydride VIII (2.5 eq.). The suspension was stirred and heated at 150°C until of a clear solution was obtained. After completion of the reaction (6 hours), ethyl acetate was added and the organic layer was washed with water, a saturated solution of NaHCO3, brine and dried over MgSO4. After evaporation of the solvent under reduced pressure, compound IX was obtained and used without further purification.
Example 1 : Following General Procedure A, N-[5-(2-allyloxymethyl-6,7-dimethoxy-benzofuran-4- ylmethyl)-4-(2,2-dimethyl-propionylamino)-pyrimidin-2-yl]-2,2-dimethyl-propionamide (quantitative yield from HPLC-MS profile) was obtained as a brown oil by reacting (5- (2-allyloxymethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)-pyrimidine-2,4-diamine) (1 eq., 5 g, 13.5mmol) and pivalic acid anhydride (2.5 eq., 7.0 ml_, 34.5 mmol). MS ESI: 539.2 [M+H]+
General Procedure B: Cleavage of allyl (Scheme 1)
Under argon, to a solution of compound IX (1 eq.) in ACN was added tetrakis- (triphenylphosphin)-palladium (0.25 eq.) and ammonium formate (5 eq.). The resulting mixture was heated at 800C until completion of the reaction. The mixture was quenched with water, and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over MgSO4, and evaporated under reduced pressure. The compound X was obtained after purification by FC (cyclohexane:EtOAc).
Example 2:
Following General Procedure B, N-[4-(2,2-dimethyl-propionylamino)-5-(2- hydroxymethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)-pyrimidin-2-yl]-2,2-dimethyl- propionamide (quantitative yield from HPLC-MS profile) was obtained by reacting N- [5-(2~allyloxymethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)-4-(2,2-dimethyl-propionyl- amino)-pyrimidin-2-yl]-2,2-dimethyl-propionamide (5 g, 9.29 mmol, 1 eq.), tetrakis- (triphenylphosphin)-palladium (2.68 g, 2.32 mmol, 0.25 eq.) and ammonium formate (2.93 g, 46.46 mmol, 5 eq.). MS ESI: 499.2 [M+Hf. Example 3:
Following General Procedure A with isobutyric anhydride to obtain N-[5-(2- allyloxymethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)-2-isobutyrylamino-pyrimidin-4- yl]-isobutyramide and following General procedure B for the cleavage of the allyl group, N-[5-(2-hydroxymethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)-2- isobutyrylamino-pyrimidin-4-yl]-isobutyramide was obtained and used for the next step without further purification. MS ESI: 471.0 [M+H]+
General Procedure C: Methylation of anthranilic acid derivatives
Under argon and at room temperature, to a solution of anthranilic acid derivative Xl wherein R8 is hydrogen (1 eq.) in ACN sodium cyanoborohydride (3.5 eq.) and formaldehyde (1.3 eq.) were added. After 5 minutes of stirring, the pH of the reaction mixture was ajusted to pH 3 with a 1 N HCI solution. After completion of the reaction, the mixture was diluted with dichloromethane, and the organic layer was washed with a saturated solution of NaHCO3 and brine. After drying over MgSO4 and evaporating under reduced pressure, the compound Xl wherein R8 is methyl was obtained and used without further purification.
Example 4:
Following General Procedure C, 4-fluoro-2-methylamino-benzoic acid (830 mg, 76%) was obtained by reacting 2-amino-4-fluoro-benzoic acid (1 g, 6.44 mmol), sodium cyanoborohydride (1.62 g, 25.76 mmol), and formaldehyde (667 μl_,, 8.37 mmol). MS ESI: 170.1 [M+H]+
Example 5:
Following General Procedure C, 4-chloro-2-methylamino-benzoic acid (1.61 g, 75%) was obtained by reacting 4-chloro-2-amino-benzoic acid (2 g, 11.66 mmol), sodium cyanoborohydride (2.93 g, 46.64 mmol), and formaldehyde (1.21 ml_, 15.16 mmol). MS ESI: 186.0 [M+H]+
General Procedure D : Amide formation (Scheme 3)
Under argon and at room temperature, to a solution of compound XIII (1 eq.) in DMF, was added amine XIV (1 to 5 eq.). 1-Hydroxybenzotriazole hydrate (1.2 eq.), (3- dimethylamino-propyl)-ethyl-carbodiimide hydrochloride (1.2 eq.) and, if needed, triethylamine (1 to 3 eq.) were then added. After completion of the reaction, the reaction mixture was diluted with ethyl acetate, and the organic layer was then washed with a 0.1 M solution of KHSO4, a saturated solution of NaHCO3, water, and brine. After drying over MgSO4 and evaporating under reduced pressure, the compound Xl was obtained and used without further purification.
Example 6:
Following General Procedure D, (2-amino-4-chloro-phenyl)-pyrrolidin-1-yl-methanone (1.37 g, 99%) was obtained by reacting 2-amino-4-chloro-benzoic acid (1 g, 5.82 mmol), pyrrolidine (578 μl_, 6.99 mmol), 1-hydroxybenzotriazole hydrate (945 mg, 6.99 mmol), and (3-dimethylamino-propyl)-ethyl-carbodiimide hydrochloride (1.34 g, 6.99 mmol). MS ESI: 225 [M+H]+
Example 7: Following General Procedure D, 2-amino-4-chloro-N,N-diethyl-benzamide (1.25 g, 95%) was obtained by reacting 2-amino-4-chloro-benzoic acid (1 g, 5.82 mmol), diethylamine (369 μl_, 6.99 mmol), 1-hydroxybenzotriazole hydrate (945 mg, 6.99 mmol), and (3-dimethylamino-propyl)-ethyl-carbodiimide hydrochloride (1.34 g, 6.99 mmol). MS ESI: 227 [M+H]+
Example 8:
Following General Procedure D, 2-amino-4-chloro-N-(1 ,3,5-trimethyl-1 H-pyrazol-4- yl)-benzamide (164 mg, 72 %) was obtained by reacting 2-amino-4-chloro-benzoic acid (140 mg, 0.79 mmol), 1 ,3,5-trimethyl-1 H-pyrazol-4-ylamine (500 mg, 3.99 mmol), 1-hydroxybenzotriazole hydrate (130 mg, 0.96 mmol), (3-dimethylamino- propyl)-ethyl-carbodiimide hydrochloride (183 mg, 0.96 mmol), and triethylamine (220 μl_, 1.60 mmol). MS ESI: 279 [M+H]+
Example 9:
Following General Procedure D, 2-amino-4-fluoro-N,N-dimethyl-benzamide (quantitative yield from HPLC-MS profile) was obtained by reacting 2-amino-4-fluoro- benzoic acid (1 g, 6.44 mmol), dimethylamine hydrochloride (630 mg, 7.73 mmol), 1- hydroxybenzotriazole hydrate (1.04 g, 7.73 mmol), (3-dimethylamino-propyl)-ethyl- carbodiimide hydrochloride (1.48 g, 7.73 mmol), and triethylamine (2.68 mL, 19.3 mmol).
MS ESI : 183.1 [M+H]+
Example 10:
Following General Procedure D, 2-amino-4-chloro-N,N-dimethyl-benzamide (10.36 g, 89%) was obtained by reacting 2-amino-4-chloro-benzoic acid (10 g, 58.3 mmol), dimethylamine hydrochloride (5.71 g, 70.0 mmol), 1-hydroxybenzotriazole hydrate (9.45 g, 70.0 mmol), (3-dimethylamino-propyl)-ethyl-carbodiimide hydrochloride (13.41 g, 70.0 mmol), and triethylamine (24.3 mL, 70.0 mmol). MS ESI : 199.0 [M+H]+
Example 11:
Following General Procedure D, 2-amino-6-fluoro-N,N-dimethyl-benzamide (1.78 g, 76 %) was obtained by reacting 2-amino-6-fluoro-benzoic acid (2 g, 12.9 mmol), dimethylamine hydrochloride (1.26 g, 15.9 mmol), 1-hydroxybenzotriazole hydrate
(2.09 g, 15.5 mmol), (3-dimethylamino-propyl)-ethyl-carbodiimide hydrochloride (2.97 g, 15.5 mmol), and triethylamine (9.4 mL, 38.7 mmol).
MS ESI : 183.1 [M+H]+
Example 12:
Following General Procedure D, 4-fluoro-N,N-dimethyl-2-methylamino-benzamide
(quantitative yield from HPLC-MS profile) was obtained by reacting 4-fluoro-2- methylamino-benzoic acid (410 mg, 2.43 mmol), dimethylamine hydrochloride (238 mg, 2.92 mmol), 1-hydroxybenzotriazole hydrate (395 mg, 2.92 mmol), (3- dimethylarnino-propyl)-ethyl-carbodiimide hydrochloride (560 mg, 2.92 mmol), and triethylamine (1.01 mL, 7.29 mmol).
MS ESI : 197.0 [M+H]+
Example 13:
Following General Procedure D, 5-chloro-N,N-dimethyl-2-methylamino-benzamide (610 mg, 71 %) was obtained by reacting 5-chloro-2-methylamino-benzoic acid (750 mg, 4.05 mmol), dimethylamine hydrochloride (396 mg, 4.86 mmol), 1- hydroxybenzotriazole hydrate (656 mg, 4.86 mmol), (3-dimethylamino-propyl)-ethyl- carbodiimide hydrochloride (931 mg, 4.86 mmol) and triethylamine (1.7 mL, 12.15 mmol). MS ESI : 213.0 [M+H]+ Example 14:
Following General Procedure D, 4-chloro-N,N-dimethyl-2-methylamino-benzamide
(859 mg, 99 %) was obtained by reacting 4-chloro-2-methylamino-benzoic acid (750 mg, 4.05 mmol), dimethylamine hydrochloride (396 mg, 4.86 mmol), 1- hydroxybenzotriazole hydrate (656 mg, 4.86 mmol), (3-dimethylamino-propyl)-ethyl- carbodiimide hydrochloride (931 mg, 4.86 mmol), and triethylamine (1.7 ml_, 12.15 mmol).
MS ESI : 213.0 [M+Hf
Example 15:
Following General Procedure D, 2-chloro-N,N-dimethyl-6-methylamino-benzamide
(309 mg, 43 %) was obtained by reacting 2-chloro-6-methylamino-benzoic acid (630 mg, 3.41 mmol), dimethylamine hydrochloride (334 mg, 4.09 mmol), 1- hydroxybenzotriazole hydrate (552 mg, 4.09 mmol), (3-dimethylamino-propyl)-ethyl- carbodiimide hydrochloride (781 mg, 4.09 mmol) and triethylamine (1.12 ml_, 10.23 mmol).
MS ESI : 213.0 [M+H]+
Example 16:
Following General Procedure D, 2-amino-3-chloro-N,N-dimethyl-benzamide (750 mg, 65 %) was obtained by reacting 2-amino-3-chloro-benzoic acid (1 g, 5.83 mmol), dimethylamine hydrochloride (571 mg, 7.00 mmol), 1 -hydroxybenzotriazole hydrate (945 mg, 7.00 mmol), (3-dimethylamino-propyl)-ethyl-carbodiimide hydrochloride (1.34 g, 7.00 mmol) and triethylamine (2.43 ml_, 17.49 mmol). MS ESI : 199.0 [M+H]+
Example 17:
Following general procedure D , 4-chloro-2-hydroxy-N,N-dimethyl-benzamide (1.82 g, 78%) was obtained by reacting 4-chloro-2-hydroxy-benzoic acid (2 g, 11.60 mmol), dimethylamine hydrochloride (1.14 g, 13.92 mmol), 1 -hydroxybenzotriazole hydrate
(1.87 g, 13.92 mmol), (3-dimethylamino-propyl)-ethyl-carbodiimide hydrochloride
(2.66 g, 13.92 mmol) and triethylamine (4.84 ml_, 34.80 mmol).
MS ESI : 200.1 (M+H) Example 18:
Following General Procedure D, 5-fluoro-2-hydroxy-N,N-dimethyl-benzamide (1.02 g, 43%) was obtained by reacting 5-fluoro-2-hydroxy-benzoic acid (2 g, 12.8 mmol), dimethylamine hydrochloride (1.25 g, 15.36 mmol), 1-hydroxybenzotriazole hydrate (2.07 g, 15.36 mmol), (3-dimethylamino-propyl)-ethyl-carbodiimide hydrochloride (2.94 g, 15.36 mmol) and triethylamine (4.88 mL, 38.78 mmol). MS ESI: 184.0 [M+H]+
Example 19: Following General Procedure D, (2-amino-4-chloro-phenyl)-morpholin-4-yl- methanone (quantitative yield from HPLC-MS profile) was obtained by reacting 2- amino-4-chloro-benzoic acid (100 mg, 0.58 mmol), morpholine (61 μl_, 0.70 mmol), 1- hydroxybenzotriazole hydrate (95 mg, 0.70 mmol), (3-dimethylamino-propyl)-ethyl- carbodiimide hydrochloride (134 mg, 0.70 mmol) and triethylamine (161 μl_, 1.16 mmol).
MS ESI: 241.1 [M+H]+
General procedure E: Amide formation with TBTU
Under argon and at room temperature, to a solution of anthranilic acid XIII (1 eq.) in DMF, were added sequentially amine XIV (5 eq.), 0-(benzotriazol-1-yl)-N,N,N',N'- tetramethyluronium tetrafluoroborate (1 to 5 eq.) and, if needed, triethylamine (2 eq.).
After completion of the reaction, the mixture was diluted with ethyl acetate and the organic layer was washed with a saturated solution of NaHCO3, water and brine. The resulting organic phase was dried over MgSO4 and evaporated under reduced pressure to give the corresponding amide Xl, which was used without further purification.
Example 20:
Following General Procedure E, 2-amino-N-benzyl-4-chloro-N-methyl-benzamide (1.52 g, 95 %) was obtained by reacting 2-amino-4-chloro-benzoic acid (1 g, 5.83 mmol), benzyl-methyl-amine (3.75 mL, 29.1 mmol), 0-(benzotriazol-1-yl)-N,N,N',N'- tetramethyluronium tetrafluoroborate (2.2 g, 6.86 mmol). MS ESI: 275.1 [M+H]+ Example 21 :
Following General Procedure E1 2-amino-N-carbamoylmethyl-4-chloro-N-methyl- benzamide (545 mg, 77%) was obtained by reacting 2-amino-4-chloro-benzoic acid (500 mg, 2.91 mmol), 2-methylamino-acetamide hydrochloride (362 mg, 2.91 mmol), 0-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (1.86 g, 5.82 mmol) and triethylamine (810 μl_, 5.82 mmol). MS ESI: 241.9 [M+H]+
Example 22: Following General Procedure E, 2-amino-4-chloro-N-isopropyl-N-methyl-benzamide (quantitative yield from HPLC-MS profile) was obtained by reacting 2-amino-3,5- dichloro-benzoic acid (10 g, 58.41 mmol), isopropyl-methyl-amine (30 ml_, 292.0 mmol), O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate (22.5 g, 70.09 mmol). MS ESI: 227.1 [M+H]+
General Procedure F: Coupling procedure using p-toluenesulfonic acid (Scheme 2)
Under argon and at room temperature, to a solution of X (1 to 1.2 eq.) in acetonitrile, p-toluenesulfonic acid (2.5 eq.) and the anthranilic acid derivative Xl (1 eq.) were added. The reaction mixture was stirred and heated at 700C until completion of the reaction. The reaction mixture was quenched with a saturated solution of NaHCO3 and extracted with dichloromethane. The organic layer was washed with water, a saturated solution of NaCI, dried over MgSO4 and evaporated under reduced pressure. The compound XII (1 eq.) so obtained was dissolved in methanol or isopropanol and an excess of a 4N NaOH solution (10 eq.) was added. The resulting mixture was heated at 500C until completion. The reaction was quenched with water, and extracted with dichloromethane. The organic layer was washed with a saturated solution of NaHCO3, water, and brine, and it was dried over MgSO4 and evaporated under reduced pressure. The compound I was obtained after purification by FC, eluting with a gradient from CH2CI2 to CH2CI2/methanol (9/1).
Example 23:
Following General Procedure F, (4-chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)- 6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-phenyl)-pyrrolidin-1 -yl-methanone (41 mg, 19%) was obtained by reacting N-[2-(2,2-dimethyl-propionylamino)-5-(2- hydroxymethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)-pyrimidin-4-yl]-2,2-dimethyl- propionamide (200 mg, 0.40 mmol), p-toluenesulfonic acid (159 mg, 0.83 mmol), (2- amino-4-chloro-phenyl)-pyrrolidin-1-yl-methanone (75 mg, 0.33 mmol), and 4N NaOH (293 μL, 1.17 mmol). MS ESI : 539.0 [M+H]+
Example 24:
Following General Procedure F, 4-chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)- 6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-N,N-diethyl-benzamide (45 mg, 21%) was obtained by reacting N-[2-(2,2-dimethyl-propionylamino)-5-(2-hydroxymethyl-6,7- dimethoxy-benzofuran-4-ylmethyl)-pyrimidin-4-yl]-2,2-dimethyl-propionamide (200 mg, 0.40 mmol), p-toluenesulfonic acid (159 mg, 0.83 mmol) 2-amino-4-chloro-N,N- diethyl-benzamide (76 mg, 0.33 mmol), and 4N NaOH (335 μL, 1.34 mmol). MS ESI : 537.0 [M+H]+
Example 25:
Following General Procedure F, (4-chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)- 6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-phenyl)-piperidin-1-yl-methanone (38 mg, 17%) was obtained by reacting N-[2-(2,2-dimethyl-propionylamino)-5-(2- hydroxymethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)-pyrimidin-4-yl]-2,2-dimethyl- propionamide (200 mg, 0.40 mmol), p-toluenesulfonic acid (159 mg, 0.83 mmol), (2- amino-4-chloro-phenyl)-piperidin-1-yl-methanone (80 mg, 0.33 mmol), and 4N NaOH (267 μL, 1.06 mmol). MS ESI : 551.0 [M+H]+
Example 26:
Following General Procedure F, 4-chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)- 6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-N-(1 ,3,5-trimethyl-1 H-pyrazol-4-yl)- benzamide (17 mg, 7%) was obtained by reacting N-[2-(2,2-dimethyl- propionylamino)-5-(2-hydroxymethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)- pyrimidin-4-yl]-2,2-dimethyl-propionamide (200 mg, 0.40 mmol), p-toluenesulfonic acid (191 mg, 1.00 mmol) and 2-amino-4-chloro-N-(1 ,3,5-trimethyl-1 H-pyrazol-4-yl)- benzamide (113 mg, 0.40 mmol) and 4N NaOH (524 μL, 2.09 mmol). MS ESI : 590.9 [M+H]+ Example 27:
Following General Procedure F, N-benzyl-4-chloro-2-{[4-(2,4-diamino-pyrimidin-5- ylmethyl)-6,7-dimethoxy-benzofuran-2-ylrnethyl]-amino}-N-methyl-benzamide (60 mg, 25%) was obtained by reacting N-[2-(2,2-dimethyl-propionylamino)-5-(2- hydroxymethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)-pyrimidin-4-yl]-2,2-dimethyl- propionamide (200 mg, 0.40 mmol), p-toluenesulfonic acid (191 mg, 1.00 mmol), 2- amino-N-benzyl-4-chloro-N-methyl-benzamide (150 mg, 0.40 mmol), and 4N NaOH (757 μl_, 3.03 mmol). MS ESI : 586.9 [M+Hf
General Procedure G : Coupling with anthranilic acid derivatives and zinc chloride (Scheme 4)
Under argon, and at 00C, to a solution of X (1 eq.) in dichloromethane, sulfonyl chloride XV, e.g. methanesulfonyl chloride (1.2 eq.) and triethylamine (1.2 eq.) were added. The resulting mixture was stirred at room temperature until completion. After quenching the reaction with water, the layers were separated. The organic phase containing the compound XVI was then dried over MgSO4, and used for next synthetic step. Under argon and at room temperature, to a solution of the anthranilic acid derivative Xl (1.2 eq.) in dichloroethane, zinc chloride (1 to 1.2 eq.) was added. After stirring for 10 minutes, the previously obtained solution of XVI (1 eq.) in dichloromethane was added. After completion of the reaction, the mixture was quenched with a saturated NaHCO3 solution and extracted with dichloromethane. The organic layer was washed with water, brine, dried over MgSO4 and evaporated under reduced pressure to give compound XII, which was used without further purification.
The compound XII (1 eq.) so obtained was dissolved in methanol or isopropanol and an excess of a 4N NaOH solution (10 eq.) was added. The resulting mixture was heated at 500C until completion. The reaction was quenched with water, and extracted with dichloromethane. The organic layer was washed with a saturated solution of NaHCO3, water, brine, dried over MgSO4 and evaporated under reduced pressure. The compound I was obtained after purification by FC, eluting with a gradient from CH2CI2 to CH2CI2/methanol (9/1).
Example 28: Following General Procedure G, 4-chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)- 6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-N,N-dimethyl-benzamide (2 g, 76 %) was obtained by reacting N-[2-(2,2-dimethyl-propionylamino)-5-(2-hydroxymethyl-6,7- dimethoxy-benzofuran-4-ylmethyl)-pyrimidin-4-yl]-2,2-dimethyl-propionamide (2.57 g, 5.15 mmol), methanesulfonyl chloride (480 μl_, 6.18 mmol), triethylamine (861 μL, 6.18 mmol), zinc chloride (840 mg, 6.18 mmol), 2-amino-4-chloro-N,N-dimethyl- benzamide (1.23 g, 6.18 mmol), and 4N NaOH (2.42 ml_, 9.68 mmol). MS ESI : 51 1.2 [M+H]+
Example 29:
Following General Procedure G, 5-chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)- 6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-N,N-dimethyl-benzamide (77 mg, 25%) was obtained by reacting N-[2-(2,2-dimethy!-propionylamino)-5-(2- hydroxymethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)-pyrimidin-4-yl]-2,2-dimethyl- propionamide (300 mg, 0.60 mmol), methanesulfonyl chloride (60 μL, 0.72 mmol), triethylamine (100 μL, 0.72 mmol), zinc chloride (83 mg, 0.61 mmol), 2-amino-5- chloro-N,N-dimethyl-benzamide (121 mg, 0.61 mmol), and 4N NaOH (309 μL, 1.23 mmol).
MS ESI : 511.0 [M+H]+
Example 30:
Following General Procedure G, 4-chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)- 6,7-dimethoxy-benzofuran-2-ylmethyl]-methyl-amino}-N,N-dimethyl-benzamide (56 mg, 21 %) was obtained by reacting N-[2-(2,2-dimethyl-propionylamino)-5-(2- hydroxymethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)-pyrimidin-4-yl]-2,2-dimethyl- propionamide (250 mg, 0.50 mmol), methanesulfonyl chloride (47 μL, 0.60 mmol), triethylamine (84 μL, 0.60 mmol), zinc chloride (71 mg, 0.52 mmol), 4-chloro-N,N- dimethyl-2-methylamino-benzamide (110 mg, 0.52 mmol) and 4N NaOH (267 μL, 1.06 mmol). MS ESI : 524.9 [M+H]+
Example 31: Following General Procedure G, 4-chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)- 6,7-dimethoxy-benzofuran-2-ylmethyl]-methyl-amino}-N-methyl-benzamide (52 mg, 17%) was obtained by reacting N-[2-(2,2-dimethyl-propionylamino)-5-(2- hydroxymethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)-pyrimidin-4-yl]-2,2-dimethyl- propionamide (300 mg, 0.60 mmol), methanesulfonyl chloride (56 μL, 0.72 mmol), triethylamine (100 μL, 0.72 mmol), zinc chloride (98 mg, 0.72 mmol), 4-chloro-N- methyl-2-methylamino-benzamide (143 mg, 0.72 mmol), and 4N NaOH (318 μl_, 1.27 mmol).
MS ESI : 510.9 [M+H]+
Example 32:
Following General Procedure G, 2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7- dimethoxy-benzofuran-2-ylmethyl]-methyl-amino}-4-fluoro-N,N-dimethyl-benzamide (40 mg, 16%) was obtained by reacting N-[2-(2,2-dimethyl-propionylamino)-5-(2- hydroxymethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)-pyrimidin-4-yl]-2,2-dimethyl- propionamide (250 mg, 0.50 mmol), methanesulfonyl chloride (47 μl_, 0.60 mmol), triethylamine (84 μl_, 0.60 mmol), zinc chloride (71 mg, 0.52 mmol), 4-chloro-N,N- dimethyl-2-methylamino-benzamide (102 mg, 0.52 mmol), and 4N NaOH (236 μl_, 0.94 mmol). MS ESI : 508.9 [M+H]+
Example 33:
Following General Procedure G, 2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7- dimethoxy-benzofuran-2-ylmethyl]-amino}-5,N,N-trimethyl-benzamide (13 mg, 6.6%) was obtained by reacting N-[2-(2,2-dimethyl-propionylamino)-5-(2-hydroxymethyl-6,7- dimethoxy-benzofuran-4-ylmethyl)-pyrimidin-4-yl]-2,2-dimethyl-propionamide (280 mg, 0.40 mmol), methanesulfonyl chloride (38 μl_, 0.48 mmol), triethylamine (67 μl_, 0.48 mmol), zinc chloride (64 mg, 0.47 mmol), 2-amino-5,N,N-trimethyl-benzamide (70 mg, 0.40 mmol), and 4N NaOH (641 μL, 2.56 mmol). MS ESI : 490.9 [M+H]+
Example 34:
Following General Procedure G, 2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7- dimethoxy-benzofuran-2-ylmethyl]-amino}-6-fluoro-N,N-dimethyl-benzamide (22 mg, 11 %) was obtained by reacting N-[2-(2,2-dimethyl-propionylamino)-5-(2- hydroxymethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)-pyrimidin-4-yl]-2,2-dimethyl- propionamide (287 mg, 0.40 mmol), methanesulfonyl chloride (31 μL, 0.40 mmol), triethylamine (56 μL, 0.40 mmol), zinc chloride (66 mg, 0.40 mmol), 2-amino-6-fluoro- N,N-dimethyl-benzamide (74 mg, 0.40 mmol) and 4N NaOH (593 μL, 2.37 mmol). MS ESI : 495.1 [M+H]+ Example 35:
Following General Procedure G, 2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7- dimethoxy-benzofuran-2-ylmethyl]-amino}-N,N-dimethyl-benzamide (55 mg, 23%) was obtained by reacting N-[2-(2,2-dimethyl-propionylamino)-5-(2-hydroxymethyl-6,7- dimethoxy-benzofuran-4-ylmethyl)-pyrimidin-4-yl]-2,2-dimethyl-propionamide (250 mg, 0.50 mmol), methanesulfonyl chloride (47μL, 0.60 mmol), triethylamine (84 μl_, 0.60 mmol), zinc chloride (82 mg, 0.60 mmol), 2-amino-N,N-dimethyl-benzamide (98 mg, 0.60 mmol), and 4N NaOH (340 μl_, 1.37 mmol). MS ESI: 477.0 [M+H]+
Example 36:
Following General Procedure G, 2-{[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7- dimethoxy-benzofuran-2-ylmethyl]-methyl-amino}-N,N-dimethy!-benzamide (68 mg, 23%) was obtained by reacting N-[2-(2,2-dimethyl-propionylamino)-5-(2- hydroxymethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)-pyrimidin-4-yl]-2,2-dimethyl- propionamide (300 mg, 0.60 mmol), methanesulfonyl chloride (60 μl_, 0.72 mmol), triethylamine (100 μl_, 0.72 mmol), zinc chloride (83 mg, 0.61 mmol), 2-amino-N,N- dimethyl-benzamide (109 mg, 0.61 mmol), and 4N NaOH (286 μl_, 1.14 mmol). MS ESI : 491.0 [M+H]+
Example 37:
Following General Procedure G, 2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7- dimethoxy-benzofuran-2-ylmethyl]-amino}-3-methoxy-N,N-dimethyl-benzamide (25.8 mg, 13%) was obtained by reacting N-[2-(2,2-dimethyl-propionylamino)-5-(2- hydroxymethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)-pyrimidin-4-yl]-2,2-dimethyl- propionamide (280 mg, 0.40 mmol), methanesulfonyl chloride (37 μl_, 0.48 mmol), triethylamine (67 μl_, 0.48 mmol), zinc chloride (64 mg, 0.47 mmol), 2-amino-3- methoxy-N,N-dimethyl-benzamide (76 mg, 0.40 mmol), and 4N NaOH (666 μl_, 1.92 mmol). MS ESI : 507.1 [M+H]+
General Procedure H: Oxidation of alcohol into aldehyde (Scheme 5)
Under argon and at room temperature, to a solution of compound X (1 eq.) in dichloromethane, manganese dioxide (10 eq.) was added at room temperature. The suspension was stirred under argon until completion. The resulting reaction mixture was filtered over celite, dried over MgSO4 and the solvent evaporated under reduced pressure. The compound XVII was obtained after purification by FC, eluting with a gradient from cyclohexane to cyclohexane/EtOAc (1/2).
Example 38: Following General Procedure H, N-[2-(2,2-dimethyl-propionylamino)-5-(2-formyl-6,7- dimethoxy-benzofuran-4-ylmethyl)-pyrimidin-4-yl]-2,2-dimethyl-propionamide (650 mg, 27%) was obtained by reacting N-[2-(2,2-dimethyl-propionylamino)-5-(2- hydroxymethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)-pyrimidin-4-yl]-2,2-dimethyl- propionamide (2.85 g, 5.73 mmol) and manganese dioxide (5.0 g, 57.37 mmoi). MS ESI: 497.1 [M+H]+
Example 39:
Following General Procedure H, N-[5-(2-Formyl-6,7-dimethoxy-benzofuran-4- ylmethyl)-2-isobutyrylamino-pyrimidin-4-yl]-isobutyramide was obtained and used for the next step without further purification. MS ESI: 469.0 [M+H]+
General Procedure I: Reductive amination with p-TosOH (Scheme 5)
Under argon and at room temperature, to a solution of compound XVII (1 eq.) and anthranilic acid derivative Xl (1 eq.) in toluene was added p-toluenesulfonic acid (0.2 eq.). The resulting mixture was heated at 11O0C for 5 days. Sodium borohydride (2 eq.) was added and the mixture was stirred at room temperature. After the reaction was completed, the mixture was quenched with water, extracted with dichloromethane, and the organic layer was washed with a saturated solution of NaHCO3, brine. After drying over MgSO4 and evaporation of the solvent under reduced pressure, compound XII was obtained. The compound XII (1 eq.) thus obtained was dissolved in methanol or isopropanol and an excess of a 4N NaOH solution (10 eq.) was added. The resulting mixture was heated at 500C until completion. The reaction was quenched with water and extracted with dichloromethane. The organic layer was washed with a saturated solution of NaHCO3, water, brine, dried over MgSO4, and evaporated under reduced pressure. Compound I was obtained after purification by FC, eluting with a gradient from CH2CI2 to CH2CI2/methanol (9/1).
Example 40:
Following General Procedure I, 4-chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7- dimethoxy-benzofuran-2-ylmethyl]-amino}-N,N-dimethyl-benzamide (18 mg, 35%) was obtained by reacting N-[2-(2,2-dimethyl-propionylamino)-5-(2-formyl-6,7- dimethoxy-benzofuran-4-ylmethyl)-pyrimidin-4-yl]-2,2-dimethyl-propionamide (50 mg, 0.1 mmol), 2-amino-4-chloro-N,N-dimethyl-benzamide (20 mg, 0.1 mmol), p- toluenesulfonic acid (4 mg, 0.02 mmol), and sodium borohydride (8 mg, 0.2 mmol). MS ESI: 510.1 [M+Hf
General Procedure J: Reductive amination with TFA (Scheme 6)
Under argon and at room temperature, to a solution of compound XVII (1 eq.) in THF freshly distilled, was added aniline XVIII (1 eq.) and trifluoroacetic acid (2 to 6 eq). The resulting mixture was stirred and heated at 500C for 3 hours. After cooling at - 10°C, sodium triacetoxyborohydride (2 to 3 eq) was added. The reaction mixture was stirred at room temperature until completion. The mixture was diluted with ethyl acetate, and the organic layer was then washed with a saturated solution of NaHCO3, dried over MgSO4, and evaporated under reduced pressure. The intermediate obtained was used for the next step without further purification.
Example 41 :
Following General Procedure J, the mixture XIX (see scheme 6) containing 2-{[4- (2,4-bis-isobutyrylamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]- amino}-4-chloro-benzoic acid and 2-{[4-(2-amino-4-isobutyrylamino-pyrimidin-5- ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethylj-amino}-4-chloro-benzoic acid (ratio 1 :2) (quantitative yield from HPLC-MS profile) was obtained by reacting N-[5-(2- Formyl-6,7-dimethoxy-benzofuran-4-ylmethyl)-2-isobutyrylamino-pyrimidin-4-yl]- isobutyramide (1 g, 2.13 mmol), 2-amino-4-chloro-benzoic acid (366 mg, 2.13 mmol), trifluoroacetic acid (327 μL, 4.27 mmol), and sodium triacetoxyborohydride (1.35 g, 6.40 mmol). This mixture was used without further purification in the general procedure O. MS ESI: 624.3 [M+H]+ MS ESI: 554.2 [M+H]+
Example 42:
Following General Procedure J, 2-{[4-(2-amino-4-isobutyrylamino-pyrimidin-5- ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-4-chloro-N-isopropyl-N- methyl-benzamide (3.6 g, 55%) was obtained by reacting N-[5-(2-Formyl-6,7- dimethoxy-benzofuran-4-ylmethyl)-2-isobutyrylamino-pyrimidin-4-yl]-isobutyramide (5 g, 10.68 mmol), 2-amino-4-chloro-N-isopropyl-N-methyl-benzamide (2.4 g, 10.68 mmol), trifluoroacetic acid (2.45 mL, 32.04 mmol), sodium triacetoxyborohydride (6.79 g, 32.04 mmol). MS ESI: 609.0 [M+H]+
S Example 43:
Following General Procedure J, N-(4-Amino-5-{2-[(5-chloro-2-cyano-phenylamino)- methyl]-6,7-dimethoxy-benzofuran-4-ylmethyl}-pyrimidin-2-yl)-isobutyramide (quantitative yield from HPLC-MS profile) was obtained by reacting N-[5-(2-formyl- 6,7-dimethoxy-benzofuran-4-ylmethyl)-2-isobutyrylamino-pyrimidin-4-yl]- 0 isobutyramide (100 mg, 0.21 mmol), 2-amino-4-chloro-benzonitrile (33 mg, 0.21 mmol), trifluoroacetic acid (33 μl_, 0.42 mmol), sodium triacetoxyborohydride (90 mg, 0.42 mmol). MS ESI: 535 [M+H]+
S Example 44:
Following General Procedure J, N-[4-amino-5-(2-{[5-chloro-2-(morpholine-4- carbonyl)-phenylamino]-methyl}-6,7-dimethoxy-benzofuran-4-ylmethyl)-pyrimidin-2- y[]-isobutyramide (quantitative yield from HPLC-MS profile) was obtained by reacting N-[5-(2-formyl-6,7-dimethoxy-benzofuran-4-ylmethyl)-4-isobutyrylamino-pyrimidin-2- 0 yl]-isobutyramide (100 mg, 0.21 mmol), (2-amino-4-chloro-phenyl)-morpholin-4-yl- methanone (51 mg, 0.21 mmol), trifluoroacetic acid (98 μL, 1.28 mmol), sodium triacetoxyborohydride (135 mg, 0.64 mmol). MS ESI: 623.0 [M+H]+
5 General procedure K: Deprotection of diaminopyrimidine (Scheme 6)
The compound (1 eq.) obtained following the general procedure J was dissolved in methanol or isopropanol and an excess of a 4N NaOH solution (4 to 10 eq.) was added. The resulting mixture was heated at 5O0C. After completion, the reaction was quenched with water and extracted with dichloromethane. The organic layer was 0 washed with a saturated solution of NaHCO3, water, brine, dried over MgSO4, and evaporated under reduced pressure. The compound I was obtained after purification by FC, eluting with a gradient from CH2CI2 to CH2CI2/methanol (9/1).
Example 45: 5 Following General Procedure K, 4-chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)- 6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-benzoic acid (10 mg, 13%) was obtained by reacting the mixture XIX (see scheme 6) containing 2-{[4-(2,4-Bis- isobutyrylamino-pyrirnidin-S-ylmethyl^δ.y-climethoxy-benzofuran^-ylrnethylJ-amino}- 4-chloro-benzoic acid and 2-{[4-(2-Amino-4-isobutyrylamino-pyrimidin-5-ylmethyl)- 6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-4-chloro-benzoic acid (ratio 1 :2) described in the general procedure J (100 mg, 0.16 mmol) and 4 N NaOH (400 μl_, 1.6 mmol). MS ESI: 484.3 [M+H]+
Example 46: Following General Procedure K, 4-chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)- 6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-N-isopropyl-N-methyl-benzamide (908 mg, 28.5%) was obtained by reacting 2-{[4-(2-amino-4-isobutyrylamino-pyrimidin-5- ylmethyO-δy-dimethoxy-benzofuran^-ylmethyll-aminoJ^-chloro-N-isopropyl-N- methyl-benzamide (3.6 g, 5.9 mmol) and 4N NaOH (5.34 ml_, 21.36 mmol) MS ESI: 539.0 [M+H]+
Example 47:
Following General Procedure K, 4-chloro-2-{[4-(2,4-diamino-pyhmidin-5-ylmethyl)- 6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-benzonitrile (24 mg, 25%) was obtained by reacting N-(4-amino-5-{2-[(5-chloro-2-cyano-phenylamino)-methyl]-6,7- dimethoxy-benzofuran-4-ylmethyl}-pyrimidin-2-yl)-isobutyramide (128 mg, 0.21 mmol) and 4N NaOH (213 μl_, 0.85 mmol) MS ESI: 465.0 [M+H]+
Example 48:
Following General Procedure K, (4-chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)- 6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-phenyl)-morpholin-4-yl-methanone (47 mg, 25%) was obtained by reacting N-[4-Amino-5-(2-{[5-chloro-2-(morpholine-4- carbonyl)-phenylamino]-methyl}-6,7-dimethoxy-benzofuran-4-ylmethyl)-pyrimidin-2- yl]-isobutyramide (213 mg, 0.34 mmol) and 4N NaOH (342 μl_, 1.37 mmol) MS ESI: 553.1 [M+H]+
General Procedure L: Amide formation and deprotection (Scheme 6)
Under argon and at room temperature, to a suspension in dichloromethane of the mixture XIX previously described in the general procedure J (1 eq.), 1- hydroxybenzotriazole hydrate (1.2 eq.), (3-dimethylamino-propyl)-ethyl-carbodiimide hydrochloride (1.2 eq.) and the amine XIV (1.2 eq.) were added. The resulting mixture was stirred at 400C until completion. The mixture was diluted with dichloromethane, washed with a saturated solution of NaHCO3 and brine. After drying over MgSO4 and evaporation of the solvent under reduced pressure, compound was obtained.
The compound (1 eq.) so obtained was dissolved in methanol or isopropanol and an excess of a 4N NaOH solution (6 eq.) was added. The resulting mixture was heated at 500C overnight or 10 minutes at 11O0C in the microwave. The reaction was quenched with water and extracted with dichloromethane. The organic layer was washed with a saturated solution of NaHCO3, water, brine, dried over MgSO4, and evaporated under reduced pressure. The compound I was obtained after purification by FC, eluting with a gradient from CH2CI2 to CH2CI2/methanol (9/1).
Example 49: Following General Procedure L, 4-chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)- 6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-N-isopropyl-N-methyl-benzamide (18 mg, 9%) was obtained by reacting mixture XIX (see scheme 6) containing 2-{[4-(2,4- bis-isobutyrylamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]- amino}-4-chloro-benzoic acid and 2-{[4-(2-amino-4-isobutyrylamino-pyrimidin-5- ylmethyO-δJ-dimethoxy-benzofuran^-ylmethyll-aminoJ^-chloro-benzoic acid (ratio 1 :2) (200 mg, 0.32 mmol), 1 -hydroxybenzotriazole hydrate (52 mg, 0.38 mmol), (3- dimethylamino-propyl)-ethyl-carbodiimide hydrochloride (74 mg, 0.38 mmol), N- isopropylmethylamine (28 mg, 0.38 mmol) and 4N NaOH (480 μl_, 1.92 mmol). MS ESI: 539.3 [M+H]+
Example 50:
Following General Procedure L, N-butyl-4-chloro-2-{[4-(2,4-diamino-pyrimidin-5- ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-N-methyl-benzamide (16 mg, 9%) was obtained by reacting mixture XIX (see scheme 6) containing 2-{[4-(2,4-bis- isobutyrylamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}- 4-chloro-benzoic acid and 2-{[4-(2-amino-4-isobutyrylamino-pyrimidin-5-ylmethyl)- 6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-4-chloro-benzoic acid (ratio 1 :2) (200 mg, 0.32 mmol), 1 -hydroxybenzotriazole hydrate (52 mg, 0.38 mmol), (3- dimethylamino-propyl)-ethyl-carbodiimide hydrochloride (74 mg, 0.38 mmol), N- butylmethylamine (34 mg, 0.38 mmol) and 4N NaOH (480 μl_, 1.92 mmol). MS ESI: 553.3 [M+H]+ Example 51 :
Following General Procedure L, 4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)- 6J-dimethoxy-benzofuran-2-ylmethyl]-amino}-N-(2-dimethylamino-ethyl)-N-methyl- benzamide (15 mg, 8%) was obtained by reacting mixture XIX (see scheme 6) containing 2-{[4-(2,4-Bis-isobutyrylamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy- benzofuran-2-ylmethyl]-amino}-4-chloro-benzoic acid and 2-{[4-(2-Amino-4- isobutyrylamino-pyrimidin-δ-ylmethyO-ΘJ-dimethoxy-benzofuran^-ylmethyO-amino}- 4-chloro-benzoic acid (ratio 1 :2) (200 mg, 0.32 mmol), 1-hydroxybenzotriazole hydrate (52 mg, 0.38 mmol), (3-dimethylamino-propyl)-ethyl-carbodiimide hydrochloride (74 mg, 0.38 mmol), N-N-N'-trimethylendiamine (39 mg, 0.38 mmol) and 4N NaOH (480 μL, 1.92 mmol). MS ESI: 568.3 [M+H]+
Example 52:
Following General Procedure L, (4-chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)- 6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-phenyl)-[4-(2-dimethylamino-ethyl)- piperazin-1-yl]-methanone (10 mg, 5%) was obtained by reacting mixture XIX (see scheme 6) containing 2-{[4-(2,4-bis-isobutyrylamino-pyrimidin-5-ylrnethyl)-6,7- dimethoxy-benzofuran-2-ylmethyl]-amino}-4-chloro-benzoic acid and 2-{[4-(2-amino- 4-isobutyrylamino-pyhmidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]- amino}-4-chloro-benzoic acid (ratio 1 :2) (200 mg, 0.32 mmol), 1- hydroxybenzotriazole hydrate (52 mg, 0.38 mmol), (3-dimethylamino-propyl)-ethyl- carbodiimide hydrochloride (74 mg, 0.38 mmol), Dimethyl-(2-piperazin-1-yl-ethyl)- amine (60 mg, 0.38 mmol) and NaOH 4N (480 μL, 1.92 mmol). MS ESI: 623.4 [M+Hf
Example 53:
Following General Procedure L, 4-chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)- 6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-phenyl)-[4-(2-methoxy-ethyl)- piperazin-1-yl]-methanone (18 mg, 9%) was obtained by reacting mixture XIX (see scheme 6) containing 2-{[4-(2,4-bis-isobutyrylamino-pyrimidin-5-ylmethyl)-6,7- dimethoxy-benzofuran-2-ylmethyl]-amino}-4-chloro-benzoic acid and 2-{[4-(2-amino- 4-isobutyrylamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]- amino}-4-chloro-benzoic acid (ratio 1 :2) (200 mg, 0.32 mmol), 1- hydroxybenzotriazole hydrate (52 mg, 0.38 mmol), (3-dimethylamino-propyl)-ethyl- carbodiimide hydrochloride (74 mg, 0.38 mmol), 1-(2-methoxy-ethyl)-piperazine (55 mg, 0.38 mmol) and 4N NaOH (480 μL, 1.92 mmol). MS ESI: 610.6 [M+H]+
Procedure M: Reductive amination with triethylorthoformate
Under argon and at room temperature, to a solution of compound XVII (1 eq.) in isopropanol, triethylorthoformate (2.8 eq.) and the anthranilic acid derivative Xl (1 eq.) were added. The resulting mixture was stirred at 500C overnight. Sodium borohydride (4 eq.) was then added at room temperature. The mixture was then stirred at 50°C until completion. The mixture was diluted with dichloromethane, washed with a saturated solution of NaHCO3 and brine. After drying over MgSO4 and evaporation of the solvent under reduced pressure, the compound (1 eq.) so obtained was dissolved in methanol or isopropanol and an excess of a 4N NaOH solution (6 eq.) was added. The resulting mixture was heated at 50°C until completion. The reaction was quenched with water and extracted with dichloromethane. The organic layer was washed with a saturated solution of NaHCO3, water, brine, dried over MgSO4, and evaporated under reduced pressure. The compound was obtained after purification by FC, eluting with a gradient from CH2CI2 to CH2CI2/methanol (9/1).
Example 54:
Following General Procedure M, N-carbamoylmethyl-4-chloro-2-{[4-(2,4-diamino- pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-N-methyl- benzamide (7 mg, 3%) was obtained by reacting N-[5-(2-formyl-6,7-dimethoxy- benzofuran-4-ylmethyl)-2-isobutyrylamino-pyrimidin-4-yl]-isobutyramide (200 mg, 0.43 mmol), 2-amino-N-carbamoylmethyl-4-chloro-N-methyl-benzamide (103 mg, 0.43 mmol), triethylorthoformate (130 μL, 1.19 mmol) and NaBH4 (64 mg, 1.71 mmol) MS ESI: 554.1 [M+H]+
General Procedure N: Coupling procedure with anthranilic acid derivatives (Scheme 7)
Under argon and at room temperature, to a solution of the anthranilic acid derivative Xl (1.1 eq.) in acetonitrile, compound XX (1 eq.) and triethylamine (1.1 eq.) were added stepwise. The resulting mixture was heated at 800C until completion. Ethyl acetate was added to the mixture and the organic layer was washed with water, a saturated solution of NaHCO3 and brine. After drying over MgSO4 and evaporation of the solvent under reduced pressure, compound I was purified by FC, eluting with a gradient from CH2CI2 to CH2CI2/methanol (93/7).
Example 55:
Following General Procedure N, 2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7- dimethoxy-benzofuran-2-ylmethyl]-amino}-4-fluoro-N,N-dimethyl-benzamide (20 mg, 3.5%) was obtained by reacting 5-(2-chloromethyl-6,7-dimethoxy-benzofuran-4- ylmethyl)-pyrimidine-2,4-diarnine hydrochloride (443 mg, 1.15 mmol), 2-amino-4- fluoro-N,N-dimethyl-benzamide (230 mg, 1.26 mmol), and triethylamine (175 μl_, 1.26 mmol). MS ESI: 495.0 [M+H]+
Example 56: Following General Procedure N, 3-chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)- 6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-N,N-dimethyl-benzamide (20 mg, 2.5%) was obtained by reacting 5-(2-chloromethyl-6,7-dimethoxy-benzofuran-4- ylmethyl)-pyrimidine-2,4-diamine hydrochloride (662 mg, 1.71 mmol), 2-amino-3- chloro-N,N-dimethyl-benzamide (375 mg, 1.89 mmol), and triethylamine (263 μl_, 1.89 mmol)
MS ESI: 511.2 [M+H]+
Example 57:
Following General Procedure N, 3,6-dichloro-2-{[4-(2,4-diamino-pyrimidin-5- ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]-amino}-N,N-dimethyl-benzamide
(19.2 mg, 2%) was obtained by reacting 5-(2-chloromethyl-6,7-dimethoxy- benzofuran-4-ylmethyl)-pyrimidine-2,4-diamine hydrochloride (665 mg, 1.72 mmol), 2-amino-3,5-dichloro-N,N-dimethyl-benzamide (440 mg, 1.89 mmol), and triethylamine (263 μl_, 1.89 mmol). MS ESI: 544.9 [M+H]+
General Procedure O: Coupling with phenol (Scheme 7)
Under argon and at room temperature, to a solution of phenol XXI (1.5 eq.) in DMF, sodium hydride 60% in oil (1.5 eq.) was added. After stirring for 30 minutes, a solution of compound XX in DMF was added. The resulting mixture was stirred at room temperature until completion of the reaction. The excess of solvent was evaporated under reduced pressure and the residue thus obtained was dissolved in dichloromethane, and washed with a saturated solution of NaHCO3 and brine. After drying over MgSO4 and evaporation of the solvent under reduced pressure, compound I was purified by FC, eluting with a gradient from CH2CI2 to CH2CI2/methanol (9/1).
Example 58:
Following General Procedure O, 3,5-dichloro-2-[4-(2,4-diamino-pyrimidin-5-ylmethyl)- 6,7-dimethoxy-benzofuran-2-ylmethoxy]-N,N-dimethyl-benzamide (98 mg, 15%) was obtained by reacting 5-(2-chloromethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)- pyrimidine-2,4-diamine hydrochloride (450 mg, 1.16 mmol), 3,5-dichloro-2-hydroxy- N,N-dimethyl-benzamide (410 mg, 1.75 mmol), and sodium hydride (70 mg, 1.75 mmol). MS ESI: 547.2 [M+H]+
Example 59:
Following General Procedure O, 4-chloro-2-[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7- dimethoxy-benzofuran-2-ylmethoxy]-N-methyl-benzamide (36 mg, 10%) was obtained by reacting 5-(2-chloromethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)- pyrimidine-2,4-diamine hydrochloride (280 mg, 0.72 mmol), 4-chloro-2-hydroxy-N- methyl-benzamide (201 mg, 1.09 mmol) and sodium hydride (44 mg, 1.09 mmol). MS ESI: 498.0 [M+H]+
Example 60: Following Genera! Procedure O, 2-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7- dimethoxy-benzofuran-2-ylmethoxy]-5-fluoro-N,N-dimethyl-benzamide (44 mg, 7%) was obtained by reacting 5-(2-chloromethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)- pyrimidine-2,4-diamine hydrochloride (480 mg, 1.24 mmol), 5-Fluoro-2-hydroxy-N,N- dimethyl-benzamide (342 mg, 1.87 mmol), and sodium hydride (75 mg, 1.87 mmol). MS ESI: 496.2 [M+H]+ Example 61 :
Following General Procedure O, 4-chloro-2-[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7- dimethoxy-benzofuran-2-ylmethoxy]-N,N-dimethyl-benzamide (1.3 mg, 3.5%) was obtained by reacting 5-(2-chloromethyl-6,7-dimethoxy-benzofuran-4-ylmethyl)- pyrimidine-2,4-diamine hydrochloride (280 mg, 0.72 mmol), 4-chloro-2-hydroxy-N,N- dimethyl-benzamide (217 mg, 1.09 mmol) and sodium hydride (44 mg, 1.09 mmol). MS ESI: 512.1 [M+H]+
General Procedure P: Measurement of antimicrobial activity Antimicrobial susceptibility testing was performed in accordance with the National Committee for Clinical Laboratory Standards (NCCLS) procedure [M7-A5, 2001]. M7-A5 (2001) : Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard —Fifth Edition American National Standard
General Procedure Q: Purified Enzymes and DHFR Enzyme Assay:
Bacterial and human dihydrofolate reductases were purified, shown to be functional and used in DHFR assays as described by Baccanari & Joyner (Baccanari, D. P. and Joyner, S. S. 1981. Dihdrofolate reductase hysteresis and its effect on inhibitor binding analyses. Biochem. 20, 1710-1716)

Claims

Claims
1. Compounds of the general formula I
Figure imgf000041_0001
wherein
R1 represents the groups
Figure imgf000041_0002
whereby in these groups R5 is cyano, carboxylic acid or the group
Figure imgf000041_0003
R9 represents hydrogen, lower alkyloxy, lower alkylamino, lower alkyl with 1 to 6 carbon atoms, aminocarbonylalkyl, mono- or dialkylaminoalkyl, alkyloxyalkyl, arylalkyl, aryl, heteroaryl, whereby the aryl and heteroaryl group optionally are mono- di- or tri- substituted with straight or branched chain lower alkyl with 1 to 4 carbon atoms, whereby these substituents may be the same or different;
R10 represents hydrogen, lower alkyl with 1 to 4 carbon atoms; R9 and R10 together with the nitrogen atom to which they are attached, form a 3-, A-, 5- or 6- membered heterocyclic ring, whereby the 5- or 6- membered rings optionally contain an additional heteroatom which can be the same or different and are oxygen, nitrogen or sulfur, whereby the additional nitrogen can be substituted with lower alkyl with 1 to 4 carbon atoms, mono- or dialkylaminoalkyl or alkyloxyalkyl;
R6 represents hydrogen, halogen, straight or branched chain lower alkyl with 1 to 4 carbon atoms, or lower alkyloxy;
R7 represents hydrogen or halogen;
R8 represents hydrogen or straight or branched chain lower alkyl with 1 to 4 carbon atoms;
R2 and R3 independently represent hydrogen, lower alkyl with 1 to 3 carbon atoms; or together a lower alkylene group with 1 to 3 carbon atoms bridging the oxygen atoms and forming a five, six or seven membered ring;
R4 represents hydrogen or lower alkyl with 1 to 4 carbon atoms;
and pharmaceutically acceptable salts thereof.
2. Compounds of the general formula Il
Figure imgf000042_0001
wherein
R2 and R3 represent methyl;
R4 represents hydrogen; Fr, Fc, R' and R8 are as defined in formula I;
3. Compounds of the general formula
Figure imgf000043_0001
Formula
wherein
R2 and R3 represent methyl;
R4 represents hydrogen and
R5, R6, R7 and R8 are as defined in formula I;
4. Compounds of the general formula IV
Figure imgf000043_0002
Formula IV
wherein
R2 and R3 represent methyl;
R4 represents hydrogen and
R5, R6, R7 and R8 are as defined in formula I;
5. Compounds of the general formula V
Figure imgf000044_0001
wherein
R2 and R3 represent methyl;
R4 represents hydrogen and
R5, R6 and R7 are as defined in formula I;
6. Compounds of the general formula Vl
Figure imgf000044_0002
Formula Vl
wherein
R2 and R3 represent methyl;
R4 represents hydrogen and
R5, R6 and R7 are as defined in formula I;
7. Compounds of formula I1 II, III, IV, V and Vl wherein
R5 is carboxylic acid dimethylamide, carboxylic acid methylamide, carboxylic acid diethylamide, carboxylic acid methoxymethylamide, pyrrolidin-1-yl-methanone, morpholin-4-yl-methanone, carboxylic acid methylamide, piperidin-1-yl-methanone; carboxylic acid N-(1 ,3,5-trimethyl-1 H-pyrazol-4-yl)-amide, carboxylic acid N-methyl- benzyl-amide, 4-(2-methoxy-ethyl)-piperazin1-yl-methanone, 4-(2-dimethylamino- ethyl)-piperazin1-yl-methanone, carboxylic acid N-(2-dimethylamino-ethyl)-N-methyl- amide, carboxylic acid N-butyl-N-methyl-amide, carboxylic acid N-isopropyl-N- methyl-amide, carboxylic acid N-carbamoylmethyl-N-methyl-amide , carboxylic acid or cyano;
R6 represents hydrogen, fluoro, chloro or methoxy; R7 represents hydrogen, fluoro or chloro; R8 represents hydrogen or methyl.
8. Compounds selected from the group consisting of:
(4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-phenyl)-pyrrolidin-1-yl-methanone
4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-N,N-diethyl-benzamide (4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-phenyl)-piperidin-1-yl-methanone
4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-N-(1 ,3,5-trimethyl-1H-pyrazol-4-yl)-benzamide
N-Benzyl-4-chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy- benzofuran-2-ylmethyl]-amino}-N-methyl-benzamide
4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-N,N-dimethyl-benzamide
5-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-N,N-dimethyl-benzamide 4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-methyl-amino}-N,N-dimethyl-benzamide
4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-methyl-amino}-N-methyl-benzamide
2-{[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]- methyl-amino}-4-fluoro-N,N-dimethyI-benzamide
2-{[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]- amino}-5,N,N-trimethyl-benzamide
2-{[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]- amino}-6-fluoro-N,N-dimethyl-benzamide 2-{[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]- amino}-N,N-dimethyl-benzamide 2-{[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]- amino}-4-fluoro-N,N-dimethyl-benzamide
3-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-N,N-dimethyl-benzamide 3,5-Dichloro-2-[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethoxy]-N,N-dimethyl-benzamide
4-Chloro-2-[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dinnethoxy-benzofuran-2- ylmethoxy]-N-methyl-benzamide
2-[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethoxy]-5- fluoro-N,N-dimethyl-benzamide
2-{[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dinnethoxy-benzofuran-2-ylmethyl]- amino}-3-methoxy-N,N-dimethyl-benzamide
2-{[4-(2,4-Diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2-ylmethyl]- methyl-amino}-N,N-dimethyl-benzamide 3,6-Dichloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-N,N-dimethyl-benzamide
4-Chloro-2-[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethoxy]-N,N-dimethyl-benzamide
(4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-pheny!)-morpholin-4-yl-methanone
4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-benzonitrile
4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-N-isopropyl-N-methyl-benzamide N-Butyl-4-chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-
2-ylmethyl]-amino}-N-methyl-benzamide
4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-benzoic acid
4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-N-(2-dimethylamino-ethyl)-N-methyl-benzamide
(4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- ylmethyl]-amino}-phenyl)-[4-(2-dimethylamino-ethyl)-piperazin-1-yl]-methanone
(4-Chloro-2-{[4-(2,4-diamino-pyrimidin-5-ylmethyl)-6,7-dimethoxy-benzofuran-2- y!methyl]-amino}-phenyl)-[4-(2-methoxy-ethyl)-piperazin-1-yl]-methanone N-CarbamoylmethyW-chloro^-^^^-diamino-pyrimidin-S-ylnnethyO-δJ-dimethoxy- benzofuran-2-ylmethyl]-amino}-N-methyl-benzamide and pharmaceutically acceptable salts thereof.
9. Intermediates of the general formulae Xl, XVII and XVIII.
Figure imgf000047_0001
X XVI XViI
wherein R2, R3 and R4 have the meaning given in fomula I in claim 1 ; R11 represents straight or branched chain lower alkyl; R12 represents lower alkyl or aryl.
10. Pharmaceutical compositions comprising one or more compounds of any one of claims 1 to 8 and usual inert carrier materials.
1 1. Pharmaceutical compositions for the treatment of infections caused by Gram positive or Gram negative pathogens comprising one or more compounds of any one of claims 1 to 8 and usual inert carrier materials.
12. The compounds of any one of claims 1 to 8 for use as medicaments.
13. The compounds of any one of claims 1 to 8 for use as medicaments for the treatment of infection.
14. The compounds of any one of claims 1 to 8 for use as medicaments for the treatment of infection caused by Gram positve or Gram negative pathogens or by a mixture thereof.
15. The use of one or more compounds of any one of claims 1 to 8 as active ingredients for the production of pharmaceutical compositions.
16. The use of one or more compounds of any one of claims 1 to 8 as active ingredients for the production of pharmaceutical compositions for the treatment of infections.
17. The use of one or more compounds of any one of claims 1 to 8 as active ingredients for the production of pharmaceutical compositions for the treatment of infections caused by Gram positive or Gram negative pathogens or by a mixture thereof.
18. A process for the manufacture of pharmaceutical compositions containing one or more compounds as claimed in any one of claims 1 to 8 as active ingredients which process comprises mixing one or more active ingredients with pharmaceutically acceptable inert carrier materials and adjuvants in a manner known per se.
19. A process for the manufacture of pharmaceutical compositions for the treatment of infections caused by Gram positive or Gram negative pathogens or by a mixture thereof containing one or more compounds as claimed in any one of claims 1 to 8 as active ingredients, which process comprises mixing one or more active ingredients with pharmaceutically acceptable inert carrier materials and adjuvants in a manner known per se.
INTERNATIONAL SEARCH REPORT
International application No
PCT/EP2005/013344
A CLASSIFICATION OF SUBJECT MATTER
INV. C07D405/06 C07D405/14 A61K31/505 A61P31/04
According to International Patent Classification (IPC) or to both national classification and IPC
B FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
C07D A61K A61P
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
Electronic data base consulted during the international search (name of data base and, where practical search terms used)
EPO-Internal , WPI Data, PAJ, BEILSTEIN Data, CHEM ABS Data
C. DOCUMENTS CONSIDERED TO BE RELEVANT
Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No
WO 02/10157 A (ARPIDA AG; BURRI , KASPAR; 1-19 GILLESSEN, DIETER; GREIVELDINGER-POENARU, SO) 7 February 2002 (2002-02-07) cited in the appl ication Abstract; claims ; examples: in particular pages 48-49, examples 94, 95 ; and pages 45, 50, examples 83, 100.
EP 0096214 A (THE WELLCOME FOUNDATION 1-19 LIMITED) 21 December 1983 (1983-12-21) cited in the appl ication Abstract; claims, in particular claims 2 and 13-15; examples, e.g. nos . 25 and 27.
Xl Further documents are listed in the continuation of Box C See patent family annex
* Special categories of cited documents
"T" later document published after the international filing date or priority date and not in conflict with the application but
"A document defining the general state of the art which is not cited to understand the principle or theory underlying the considered to be of particular relevance invention
"E" earlier document but published on or after the international "X' document of particular relevance, the claimed invention filing data cannot be considered novel or cannot be considered to
"L' document which may throw doubts on priority claιm(s) or involve an inventive step when the document is taken alone which is cited to establish the publication date of another Y" document of particular relevance, the claimed invention citation or other special reason (as specified) cannot be considered to involve an inventive step when the
"O" document referring to an oral disclosure, use exhibition or document is combined with one or more other such docuother means ments, such combination being obvious to a person skilled
"P' document published prior to the international filing date but in the art later than the priority date claimed '&' document member of the same patent family
Date of the actual completion of the international search Date of mailing of the international search report
1 Oune 2006 16/06/2006
Name and mailing address of the ISA/ Authorized officer
European Patent Office, P B 5818 Patentlaan 2 NL - 2280 HV Ri|swi|k TeI (+31-70) 340-2040, Tx 31 651 epo nl, Fax (+31-70) 340-3016 Wei sbrod , T
PCT/EP2005/013344 2005-01-07 2005-12-13 Selected benzofuran derivatives Ceased WO2006072370A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2007549808A JP2008526791A (en) 2005-01-07 2005-12-13 Selected benzofuran derivatives
HU0700556A HUP0700556A2 (en) 2005-01-07 2005-12-13 Benzofuran derivatines process for their preparation the intermediates and pharmaceuticals containing them
EP05819387A EP1838704A1 (en) 2005-01-07 2005-12-13 Selected benzofuran derivatives
US11/813,241 US7524855B2 (en) 2005-01-07 2005-12-13 Selected benzofuran derivatives
AU2005324135A AU2005324135A1 (en) 2005-01-07 2005-12-13 Selected benzofuran derivatives
MX2007008149A MX2007008149A (en) 2005-01-07 2005-12-13 Selected benzofuran derivatives.
CA002594091A CA2594091A1 (en) 2005-01-07 2005-12-13 Selected benzofuran derivatives
IL183681A IL183681A0 (en) 2005-01-07 2007-06-05 Selected benzofuran derivatives
NO20073046A NO20073046L (en) 2005-01-07 2007-06-15 Selected benzofuran derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP0500072 2005-01-07
EP2005000072 2005-01-07

Publications (1)

Publication Number Publication Date
WO2006072370A1 true WO2006072370A1 (en) 2006-07-13

Family

ID=36097127

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/013344 Ceased WO2006072370A1 (en) 2005-01-07 2005-12-13 Selected benzofuran derivatives

Country Status (13)

Country Link
US (1) US7524855B2 (en)
EP (1) EP1838704A1 (en)
JP (1) JP2008526791A (en)
KR (1) KR20070094957A (en)
CN (1) CN101087779A (en)
AU (1) AU2005324135A1 (en)
CA (1) CA2594091A1 (en)
HU (1) HUP0700556A2 (en)
IL (1) IL183681A0 (en)
MX (1) MX2007008149A (en)
NO (1) NO20073046L (en)
WO (1) WO2006072370A1 (en)
ZA (1) ZA200705107B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2573073A1 (en) * 2011-09-26 2013-03-27 Sanofi Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
CN103012397A (en) * 2011-09-26 2013-04-03 赛诺菲 Pyrazolo quinolinone derivative and preparation method thereof as well as therapeutic application of derivative
US8865742B2 (en) 2010-11-28 2014-10-21 Mapi Pharma Ltd. Intermediate compounds and processes for the preparation of quinoline derivatives such as Laquinimod sodium
US9169246B2 (en) 2011-09-26 2015-10-27 Sanofi Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
CN108866019A (en) * 2018-07-18 2018-11-23 青岛农业大学 A kind of preparation method and applications recombinating streptococcus pneumonia dihyrofolate reductase

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0096214A1 (en) * 1982-05-01 1983-12-21 The Wellcome Foundation Limited Antibacterial pyrimidine compounds
WO2002010157A1 (en) * 2000-07-29 2002-02-07 Arpida Ag Benzofuran derivatives and their use as antibacterial agents
WO2005005418A1 (en) * 2003-07-11 2005-01-20 Arpida Ag Benzofuran derivatives and their use in the treatment of microbial infections

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB875562A (en) 1957-02-21 1961-08-23 Wellcome Found Improvements in and relating to pyrimidine derivatives and the preparation thereof
ZA833067B (en) * 1982-05-01 1984-12-24 Wellcome Found Antibacterial compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0096214A1 (en) * 1982-05-01 1983-12-21 The Wellcome Foundation Limited Antibacterial pyrimidine compounds
WO2002010157A1 (en) * 2000-07-29 2002-02-07 Arpida Ag Benzofuran derivatives and their use as antibacterial agents
WO2005005418A1 (en) * 2003-07-11 2005-01-20 Arpida Ag Benzofuran derivatives and their use in the treatment of microbial infections

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865742B2 (en) 2010-11-28 2014-10-21 Mapi Pharma Ltd. Intermediate compounds and processes for the preparation of quinoline derivatives such as Laquinimod sodium
US9102592B2 (en) 2010-11-28 2015-08-11 Mapi Pharma Ltd. Intermediate compounds and processes for the preparation of quinoline derivatives such as laquinimod sodium
EP2573073A1 (en) * 2011-09-26 2013-03-27 Sanofi Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
CN103012397A (en) * 2011-09-26 2013-04-03 赛诺菲 Pyrazolo quinolinone derivative and preparation method thereof as well as therapeutic application of derivative
WO2013045400A1 (en) * 2011-09-26 2013-04-04 Sanofi Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
US9169246B2 (en) 2011-09-26 2015-10-27 Sanofi Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof
CN103012397B (en) * 2011-09-26 2017-03-01 赛诺菲 Pyrazolo (E)-3-(3-Acetyl-4-hydroxy-5-methoxy-phenyl)-N-(4-hydroxy-1-methyl-3-octyloxy-2-oxo-1,2-dihydro-quinolin-7-yl)-acrylamide, its preparation method and its therapeutic use
RU2621037C2 (en) * 2011-09-26 2017-05-31 Санофи Pyrazole quinolinone derivatives, their preparation and therapeutic application
CN108866019A (en) * 2018-07-18 2018-11-23 青岛农业大学 A kind of preparation method and applications recombinating streptococcus pneumonia dihyrofolate reductase

Also Published As

Publication number Publication date
AU2005324135A1 (en) 2006-07-13
IL183681A0 (en) 2007-09-20
US7524855B2 (en) 2009-04-28
NO20073046L (en) 2007-06-25
EP1838704A1 (en) 2007-10-03
JP2008526791A (en) 2008-07-24
US20080108610A1 (en) 2008-05-08
ZA200705107B (en) 2008-06-25
HUP0700556A2 (en) 2008-09-29
CN101087779A (en) 2007-12-12
MX2007008149A (en) 2007-07-24
CA2594091A1 (en) 2006-07-13
KR20070094957A (en) 2007-09-27

Similar Documents

Publication Publication Date Title
RU2159238C2 (en) Benzofurans and method of preparation thereof
EP2398771B1 (en) Heterocyclic compounds which modulate the cb2 receptor
EP2443107B1 (en) Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor
AU2004236006B2 (en) Derivatives of piperidinyl- and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics
AU2005315392A1 (en) 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as CDK inhibitors
Temiz‐Arpacı et al. Synthesis and Antimicrobial Activity of Some 5‐[2‐(Morpholin‐4‐yl) acetamido] and/or 5‐[2‐(4‐Substituted piperazin‐1‐yl) acetamido]‐2‐(p‐substituted phenyl) benzoxazoles
Holla et al. Studies on arylfuran derivatives: part VII. Synthesis and characterization of some Mannich bases carrying halophenylfuryl moieties as promising antibacterial agents
EP3760633B1 (en) Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof
Kus et al. Synthesis and antimicrobial activity of some novel 2‐[4‐(substituted piperazin‐/piperidin‐1‐ylcarbonyl) phenyl]‐1H‐benzimidazole derivatives
EP1838704A1 (en) Selected benzofuran derivatives
WO2008098143A2 (en) Antimicrobial compounds and methods of use
CA2378603C (en) Benzofuran derivatives
Li et al. Novel arylhydrazone derivatives bearing a rhodanine moiety: synthesis and evaluation of their antibacterial activities
WO2007081901A2 (en) Pyrimidinone derivatives as protein kinase inhibitors
EP1651639B1 (en) Benzofuran derivatives and their use in the treatment of microbial infections
Aibibula et al. Synthesis and Cytotoxic Activity of a New Derivative of Rupestonic Acid
Nagaraj et al. Synthesis and biological evaluation of 3-benzyl/piperazino-methyl-1, 2, 3-triazol-4-yl)-2, 3-dihydro-1, 3, 4-thiadiazole-2-thione
HK1110867A (en) Selected benzofuran derivatives
EP0551617A2 (en) Cinnamyl piperazine derivatives method of manufacturing the same and agricultural/horticultural fungicides containing cinnamyl piperazine derivatives
CN115925706A (en) Design, synthesis and application of a class of piperazine acetyl-spiro[pyrrolidine-2,3`-quinoline]-2`-one derivatives
Pallavali Facile Synthesis of Quinoxaline Amide Derivatives and Their Antimicrobial Activity Correlated with Molecular Docking Studies
Idrees et al. Pharmaceutical Sciences

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005819387

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 183681

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2007/05107

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 200580044713.7

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2594091

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007549808

Country of ref document: JP

Ref document number: 11813241

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/008149

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 3005/CHENP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005324135

Country of ref document: AU

Ref document number: 556384

Country of ref document: NZ

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005324135

Country of ref document: AU

Date of ref document: 20051213

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005324135

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: P0700556

Country of ref document: HU

WWE Wipo information: entry into national phase

Ref document number: 1020077018133

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 183681

Country of ref document: IL

WWP Wipo information: published in national office

Ref document number: 2005819387

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11813241

Country of ref document: US